<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        23-370-06
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2006
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        ITRAZOL 100 mg capsule
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        ITRACONAZOLE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        100
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Capsule
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        4
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        34.55
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="SAJA-SAUDI ARABIAN JAPANESE PHARMACEUTICAL CO" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            SAJA-SAUDI ARABIAN JAPANESE PHARMACEUTICAL CO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 360]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Farouk, Maamoun Tamer & CO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            SAJA-SAUDI ARABIAN JAPANESE PHARMACEUTICAL CO
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J02AC02
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>ITRAZOL is indicated for the treatment of fungal infections of the vagina, skin, mouth, eyes, nails<br />and internal organs.<br />The active substance is Itraconazole, a member of the following pharmaco-therapeutic class of<br />drugs: Antimycotic for systemic use, triazole derivatives.<br />ITRAZOL is very effective against a variety of infections caused by yeasts and fungi.<br />It has great affinity for highly keratinized tissues such as skin and nails, as well as for the vaginal<br />wall lining.<br />Therapeutic levels of ITRAZOL remain in the skin for two to four weeks following the end of<br />treatment, depending on its duration.<br />In vaginal tissue, ITRAZOL can be found for a period of two to three days, again depending on the<br />duration of treatment.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take ITRAZOL if you:</strong><br />&bull; If you are allergic )hypersensitive( to any of the ingredients in ITRAZOL capsules )listed in<br />section 6 Contents of the pack and other information(<br />&bull; If you are pregnant, think you might be pregnant or could become pregnant )see &lsquo;Pregnancy<br />and breast-feeding&rsquo; below(<br />Do not take this medicine if any of the above applies to you. If you are not sure, talk to your doctor<br />or pharmacist before taking ITRAZOL capsules.<br />Tell your doctor if you are taking any medicines, before you use ITRAZOL capsules.<br />&bull;<strong> Do not use ITRAZOL capsules if </strong>you are taking any of the following medicines, or within 2 weeks<br />of stopping ITRAZOL:<br /><strong>Medicines used to treat problems with the heart, blood or circulation</strong><br />- aliskiren, eplerenone, lercanidipine, nisoldipine or Felodipine )for high blood pressure(<br />- bepridil, ivabradine or ranolazine &ndash; )for angina(<br />- dabigatran or ticagrelor )for blood clots(<br />- disopyramide, dofetilide, dronedarone or quinidine )for irregular heart beat rhythms(<br />- lomitapide, lovastatin or simvastatin )to lower cholesterol(<br />- sildenafil )for pulmonary arterial hypertension(<br />- Finerenone )used to lower the risk of serious kidney and heart problems(<br /><strong>Medicines to treat stomach problems or constipation</strong><br />- cisapride )for stomach upsets(<br />- domperidone )for nausea and vomiting(<br />- naloxegol )for constipation caused by taking opioid painkillers(<br /><strong>Medicines to treat headaches, sleep or mental health problems</strong><br />- dihydroergotamine or ergotamine )ergot alkaloids used for migraine headaches(<br />- midazolam )taken by mouth( or triazolam )for sedation or to help you sleep(<br />- lurasidone, pimozide, quetiapine or sertindole )for schizophrenia, bipolar disorder or other mental<br />health problems(<br />- Methadone )used to treat chronic pain, and it is also used to treat addiction to heroin or other<br />opioids(<br /><strong>Medicines to treat urinary problems</strong><br />- darifenacin )for urinary incontinence(<br />- fesoterodine or solifenacin )for irritated urinary bladder( when used in patients with certain kidney<br />or liver problems<br /><strong>Medicines to treat allergies</strong><br />- astemizole, mizolastine or terfenadine )for allergies(<br /><strong>Medicines to treat erection and ejaculation problems</strong><br />- avanafil )for erectile dysfunction(<br />- dapoxetine )for premature ejaculation(<br />- vardenafil )for erectile dysfunction( when used in men older than 75 years of age<br /><strong>Other medicines containing:</strong><br />- colchicine )for gout( when used in patients with kidney or liver problems<br />- ergometrine )ergonovine( or methylergometrine )methylergonovine( ergot alkaloids used after<br />giving birth<br />- eliglustat )for Gaucher&rsquo;s disease( when used in patients that cannot break down certain medicines<br />in the body<br />- halofantrine )for malaria(<br />- irinotecan )for cancer(<br />- isavuconazole )for fungal infections(<br />- ombitasvir, paritaprevir, ritonavir with or without dasabuvir &ndash; )to treat hepatitis C(<br />- Voclosporin ) for the treatment of lupus nephritis.(<br /><strong>Remember &ndash; do not take any of the medicines above for 2 weeks after your last treatment<br />with ITRAZOL capsules.</strong><br /><strong>Take special care with ITRAZOL</strong><br />Talk to your doctor or pharmacist before taking this medicine:<br />&bull; If you have ever had kidney problems. Your dose of ITRAZOL capsules may have to be changed<br />&bull; If you have ever had liver problems such as yellow skin )jaundice(. Your dose of ITRAZOL capsules<br />may need to be changed. If after taking this medicine you have a severe lack of appetite, feel sick<br />)nausea(, are sick )vomiting(, feel unusually tired, get stomach pain, muscle weakness, yellowing of<br />the skin or whites of the eyes, unusually dark urine, pale stools or hair loss, stop taking ITRAZOL<br />capsules and tell your doctor straight away<br />&bull; If you have ever had a heart problem including heart failure )also called congestive heart failure<br />or CHF(. ITRAZOL capsules could make it worse. If after taking this medicine you get any of the<br />following:<br />&bull; shortness of breath<br />&bull; unexpected weight gain<br />&bull; swelling of your legs or tummy<br />&bull; feel unusually tired<br />&bull; wake up short of breath at night<br />Stop taking ITRAZOL capsules and tell your doctor straight away. These may be signs of heart<br />failure<br />&bull; If you have Acquired Immunodeficiency Syndrome )AIDS( or your immune system is not working<br />as well as it should<br />&bull; If you have experienced an allergic reaction to another anti-fungal product in the past<br />&bull; If you have cystic fibrosis<br />If you are not sure if any of the above applies to you, talk to your doctor or pharmacist before taking<br />ITRAZOL capsules.<br /><strong>Children and the elderly</strong><br />ITRAZOL capsules are not normally given to children under the age of 12 or the elderly. However,<br />your doctor may prescribe them in special cases.<br /><strong>Blood tests</strong><br />If your ITRAZOL capsules course is for more than one month, your doctor may want to check your<br />liver by testing your blood.<br /><strong>Other medicines and ITRAZOL capsules</strong><br />Tell your doctor or pharmacist if you are taking, have recently taken or might take any other<br />medicines. This includes medicines that you buy without a prescription or herbal medicines.<br />There are some medicines that you should not take whilst taking ITRAZOL. These are listed<br />above under the heading &ldquo;Do not use ITRAZOL capsules if you are:&rdquo;<br />Certain medicines are not recommended for use with ITRAZOL capsules.<br />Your doctor may decide that you should not take some medicines at the same time as, or<br />within 2 weeks of stopping ITRAZOL capsules.<br />Examples of these medicines are:<br /><strong>Medicines to treat problems with the heart, blood or circulation</strong><br />- apixaban, rivaroxaban or vorapaxar )for blood clots(<br />- atorvastatin )to lower cholesterol(<br />- felodipine )for high blood pressure(<br />- riociguat or tadalafil )for pulmonary hypertension(<br />- Finerenone )used to lower the risk of serious kidney and heart problems(<br /><strong>Medicines to treat epilepsy, headaches or mental health problems</strong><br />- phenytoin, carbamazepine or phenobarbital )anti-epileptics(<br />- eletriptan )for migraine headaches(<br />- St John&rsquo;s Wort )Hypericum, perforatum( )a herbal medicine used for mental health problems(<br /><strong>Medicines to treat urinary problems</strong><br />- tamsulosin )for male urinary incontinence(<br />- tolterodine )for irritated urinary bladder(<br /><strong>Medicines to treat cancer</strong><br />- axitinib, bosutinib, cabazitaxel, cabozantinib, ceritinib, cobimetinib, crizotinib, dabrafenib,<br />dasatinib, docetaxel, ibrutinib, lapatinib, nilotinib, olaparib, pazopanib, regorafenib, sunitinib,<br />trabectedin, trastuzumab emtansine, Mobocertinib, Entrectinib, Pemigatinib or vinca alkaloids )eg,<br />vinflunine, vinorelbine(<br /><strong>Medicines to treat tuberculosis</strong><br />- bedaquiline, isoniazid, rifabutin or rifampicin )for tuberculosis(<br /><strong>Medicines to treat human immunodeficiency virus )HIV( or hepatitis</strong><br />- efavirenz or nevirapine )for HIV/AIDS(<br />- elbasvir/grazoprevir, simeprevir, tenofovir alafenamide fumarate )TAF(, tenofovir disoproxil<br />fumarate )TDF( )for HIV or hepatitis(<br /><strong>Medicines used after organ transplant</strong><br />- everolimus, rapamycin )also known as sirolimus(, temsirolimus<br /><strong>Medicines to treat benign prostatic enlargement</strong><br />- alfuzosin, silodosin<br /><strong>Medicines to treat lung problems or allergies</strong><br />- ciclesonide )for inflammation, asthma and allergies(<br />- ebastine )for allergies(<br />- salmeterol )for asthma or chronic obstructive pulmonary disease -COPD(<br /><strong>Medicines to treat erection and ejaculation problems</strong><br />- tadalafil or vardenafil )when used in men 75 years of age and younger( )for erectile dysfunction(<br /><strong>Other medicines containing:</strong><br />- colchicine )for gout(<br />- fentanyl )for pain(<br />- lumacaftor/ ivacaftor )for cystic fibrosis(<br />- Voclosporin ) for the treatment of lupus nephritis.(<br /><strong>Remember - do not take any of the medicines above for 2 weeks after your last treatment<br />with ITRAZOL capsules.</strong><br />This is not a complete list, so tell your doctor if you are taking or planning to take any of these<br />medicines, or any other medicines.<br />Care needs to be taken when using ITRAZOL capsules with certain other medicines.<br />You may be more likely to get side effects, or the dose of ITRAZOL capsules or the other medicine<br />might need to be changed. Examples of these medicines are:<br />M<strong>edicines to treat problems with the heart, blood or circulation</strong><br />- bosentan )for pulmonary hypertension(<br />- calcium channel blockers such as, dihydropyridines such as amlodipine, isradipine, nifedipine,<br />nimodipine or diltiazem )for hypertension(<br />- or verapamil )for high blood pressure(<br />- cilostazol )for circulatory problems(<br />- &lsquo;coumarins&rsquo; such as warfarin )for blood clots(<br />- digoxin )for atrial fibrillation(<br />- nadolol )for pulmonary hypertension or angina(<br /><strong>Medicines to treat stomach problems or diarrhoea</strong><br />- aprepitant or netupitant )for nausea and vomiting during cancer treatment(<br />- loperamide )for diarrhoea(<br />- antacids such as aluminium, calcium, magnesium, or sodium bicarbonate; H2-receptor antagonists<br />such as cimetidine, ranitidine and proton pump inhibitors such as lansoprazole, omeprazole,<br />rabeprazole )to treat stomach acid problems(<br /><strong>Medicines to treat sleep problems or mental health problem</strong>s<br />- Alprazolam, brotizolam, buspirone, or midazolam )when injected into a vein( )for anxiety or to<br />help you sleep(<br />- zopiclone )to help you sleep(<br />- reboxetine or venlafaxine )for depression and anxiety(<br />- aripiprazole, cariprazine, haloperidol or risperidone )for schizophrenia, bipolar disorder or other<br />mental health problems(<br />- galantamine )for Alzheimer&rsquo;s disease(<br />- guanfacine )for attention deficit hyperactivity disorder(<br /><strong>Medicines to treat urinary problems</strong><br />- imidafenacin, fesoterodine, oxybutynin, solifenacin )for irritated urinary bladder(<br /><strong>Medicines to treat cancer</strong><br />- bortezomib, brentuximab vedotin busulfan, erlotinib, gefitinib, idelalisib, imatinib, nintedanib,<br />panobinostat, ponatinib, ruxolitinib or sonidegib<br /><strong>Medicines to treat infections</strong><br />- ciprofloxacin, clarithromycin, or erythromycin )for bacterial infections(<br />- delamanid )for tuberculosis(<br />- artemether-lumefantrine or quinine )to treat malaria(<br />- praziquantel )for fluke and tapeworms(<br /><strong>Medicines to treat human immunodeficiency virus )HIV( or hepatitis</strong><br />- cobicistat, boosted elvitegravir, maraviroc, ritonavir, ritonavir-boosted darunavir, ritonavir-boosted</p><p>fosamprenavir, indinavir or saquinavir )for HIV(<br />- glecaprevir/pibrentasvir )for hepatitis(<br /><strong>Medicines used after organ transplant</strong><br />- cyclosporine or tacrolimus<br /><strong>Medicines to treat benign prostatic enlargement</strong><br />- dutasteride<br /><strong>Medicines to treat lung problems, allergies or inflammatory conditions</strong><br />- bilastine, or rupatadine )for allergy(<br />- methylprednisolone or dexamethasone, )medicines given by mouth or injection for asthma,<br />allergies or inflammatory conditions(<br />- budesonide or fluticasone )for asthma, allergies(<br /><strong>Medicines to treat erection and ejaculation problems</strong><br />- sildenafil )for erectile dysfunction(<br /><strong>Medicines to treat pain</strong><br />- alfentanil, buprenorphine, oxycodone or sufentanil )for pain(<br />- meloxicam )for joint inflammation and pain(<br /><strong>Other medicines containing:</strong><br />- alitretinoin )given by mouth( )for eczema(<br />- cabergoline )for Parkinson&rsquo;s disease(<br />- cannabis based products including medicines )such as for nausea and vomiting or muscle spasms<br />in patients with multiple sclerosis(<br />- cinacalcet )for an over active parathyroid(<br />- dienogest or ulipristal )contraceptives(<br />- eliglustat )for Gauchers disease( when used in patients that cannot break down certain medicines<br />in the body<br />- ivacaftor; )for cystic fibrosis(<br />- levacetylmethadol and methadone )to treat drug addiction(<br />- repaglinide or saxagliptin )for diabetes(<br />This is not a complete list, so tell your doctor if you are taking or planning to take any of these<br />medicines, or any other medicines. They may need to alter They may need to alter the dose of<br />ITRAZOL capsules or your other medicine.<br /><strong>Pregnancy</strong><br />Do not take ITRAZOL if you are pregnant. Women of childbearing age who may become pregnant<br />must use proper contraception to ensure they do not get pregnant while under treatment with<br />ITRAZOL.<br />Contraception should be used through the first normal menstrual cycle following termination of<br />ITRAZOL treatment, as the drug can remain in the system for some time.<br /><strong>Breast-feeding</strong><br />Inform your doctor if you are breast-feeding and are prescribed ITRAZOL , as small amounts of the<br />drug may be present in milk.<br />Ask your doctor or pharmacist for advice before taking any medicine.<br /><strong>Taking ITRAZOL with food and drink</strong><br />For maximum drug absorption ITRAZOL should be taken immediately following a meal.<br /><strong>Driving and using machines</strong><br />No studies on the effects on the ability to drive and use machines have been performed.<br /><strong>Important information about one of the ingredients of ITRAZOL</strong><br />This medicine contains the sugar sucrose. If you have been told by your doctor that you have<br />intolerance to some sugars, contact your doctor before taking this medicinal product.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take ITRAZOL exactly as your doctor has told you. You should check with your doctor or<br />pharmacist if you are not sure.<br /><strong>Method and route of administration</strong><br />ITRAZOL must be taken immediately following a meal for optimum absorption. Capsules should<br />be swallowed with a small amount of water.<br /><strong>Frequency and duration of treatment</strong><br />The number of capsules and the duration of treatment will depend on the fungus and on the<br />location of infection.<br />Your doctor will tell you exactly what dose to take.<br />The following table lists some of the more frequent dosages:<br /><img src="data:image/png;base64,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" alt="" width="403" height="556" vspace="0" hspace="0" border="0" style="width:403px;height:556px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></p><p><strong>When you should expect the results</strong><br />Drug effects are not immediate.<br />In skin infections, lesions normally disappear a few weeks after treatment is suspended. This is<br />characteristic of fungus lesions as the drug will eliminate the fungus but the lesions will remain<br />until new skin grows.<br />Nail lesions will disappear six to nine months after treatment, as the drug will eliminate the<br />fungus but new nail growth takes several months.<br />Do not worry if you see no improvement during the treatment.<br />The drug will remain in your nails for several months and is doing its job.<br />Suspend treatment as soon as your doctor tells you to, even if you see no visible signs of<br />improvement.<br />For infections of internal organs higher doses and longer treatment times may be required.<br />Do not forget to take your medication.<br />Follow these instructions unless your doctor tells you otherwise.<br />Your doctor will tell you how long you should take ITRAZOL .<br />Do not interrupt treatment before being advised to do so by your doctor or cure may not be<br />complete.<br /><strong>If you take more ITRAZOL than you should</strong><br />Immediately consult your doctor or pharmacist if you take more ITRAZOL than you should.<br /><strong>If you forget to take ITRAZOL</strong><br />Take the missed dose as soon as you remember it. However, if it is almost time for the next dose,<br />skip the missed dose and continue your regular dosing schedule. Do not take a double dose to<br />make up for forgotten individual doses.<br />If you have any further questions on the use of this product, ask your doctor or pharmacist.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, ITRAZOL can cause side effects, although not everybody gets them. The<br />following side effects can occur:<br /><strong>Common )affects 1 to 10 users in 100(:</strong><br />&bull; Distortion or decrease of the sense of taste )dysgeusia(<br /><strong>Uncommon )affects 1 to 10 users in 1,000(:</strong><br />&bull; Inflammation of the liver )hepatitis(, jaundice<br />&bull; Localized swelling )oedema(<br /><strong>Very rare )affects less than 1 user in 10,000(:</strong><br />&bull; Reduced number of white blood cells )leukopenia, neutropenia(<br />&bull; Reduced number of thrombocytes )thrombocytopenia(<br />&bull; Severe allergic reactions<br />&bull; Too less potassium in the blood )hypokalemia(<br />&bull; Increase of triglycerides )a type of fat( in your blood )hypertriglyceridemia (<br />&bull; Headache, dizziness<br />&bull; Pain, loss of sensation, and inability to control muscles<br />&bull; Visual disorders, including blurred or double vision )diplopia(<br />&bull; Ear buzzing )tinnitus(<br />&bull; Abdominal pain, vomiting, nausea, diarrhoea, uncomfortable fullness after meals )dyspepsia(,<br />constipation<br />&bull; Hepatic enzyme increased<br />&bull; Rash, itching )pruritus(, severe skin diseases, hair loss, increased sensitivity to sunlight<br />&bull; Muscular weakness, muscular pain and joint pain<br />&bull; Frequent daytime urination, urinary incontinence<br />&bull; Menstrual disorders, erectile dysfunction<br /><strong>Not known )frequency cannot be estimated from the available data(:</strong><br />&bull; Allergic reactions<br />&bull; Numbness and tingling )paraesthesia(, loss of sensitivity to pain or touch )hypoaesthesia(<br />&bull; Loss of heart ability to pump blood efficiently )congestive heart failure(<br />&bull; Abnormal build up of fluid in the lungs, which leads to swelling )pulmonary oedema(<br />&bull; Hepatotoxicity, acute hepatic failure<br />If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet,<br />please tell your doctor or pharmacist.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep out of the reach and sight of children.<br />Store below 25&deg;C.<br />Do not use ITRAZOL after the expiry date which is stated on the carton. The expiry date refers<br />to the last day of that month.<br />Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist<br />how to dispose of medicines no longer required. These measures will help to protect the<br />environment.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&bull; <strong>The active substance</strong> is Itraconazole. Each capsule contains 100mg of Itraconazole<br />&bull;<strong> The other ingredients </strong>are: hypromellose, poloxamer, sucrose, and maize starch.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                ITRAZOL in pink and turquoise capsules coded by SJ153, each capsule contain 100 mg
Itraconazole in a pellet formulation
In Packs of: 4 or 15 capsules.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>SAJA Pharmaceuticals<br />Saudi Arabian Japanese pharmaceutical company limited<br />Jeddah &ndash; Kingdom of Saudi Arabia<br />&nbsp;</p><p><strong>-To report any side effects)s(</strong><br /><strong>&bull; Saudi Arabia</strong><br />- The National Pharmacovigilance Centre )NPC(:<br />- SFDA Call Center: 19999<br />- E-mail: npc.drug@sfda.gov.sa<br />- Website: https://ade.sfda.gov.sa<br /><strong>&bull; Other GCC states /other countries</strong><br />-Please contact the relevant competent authority<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                January/2024
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>يُوصف إترازول لعلاج عدوى الفطريات بالمهبل، الجلد، الفم، العينين، الأظافر والأعضاء الداخلية.</p><p>المادة الفعالة هي إتراكونازول، وهي تنتمي إلى فئة الدواء العلاجية التالية: مضادات الفطريات للاستخدام الجهازي، مشتقات تريازول.</p><p>إترازول له فعالية شديدة تجاه مجموعة مختلفة من العدوى الناجمة عن الخمائر والفطريات.</p><p>إترازول له قابلية كبيرة للأنسجة المُتَقَرِّنة مثل الجلد والأظافر، فضلا عن بطانة جدار المهبل.</p><p>تبقي المستويات العلاجية من إترازول بالجلد لمدة ٢-٤ أسابيع بعد انتهاء العلاج. ويعتمد ذلك على مدة العلاج.</p><p>في أنسجة المهبل، يظل إترازول متواجدًا لفترة ٢-٣ أيام، ويعتمد ذلك أيضًا على مدة العلاج.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>لا تتناول إترازول إذا :</strong><br />&bull; إذا كنت تعاني من حساسية )فَرْطُ التَّحَسُّسِ( لأي من مكونات كبسولات إترازول )المدرجة في القسم 6<br />معلومات إضافيه)<br />&bull; إذا كنت حاملاً، تعتقدين أنك حامل أو يمكن أن تصبحي حاملاً )انظر &quot;الحمل والرضاعة&quot; أدناه(<br />لا تتناول هذا الدواء إذا كان ينطبق عليك أي مما سبق. إذا لم تكن متأكدًا، تحدث إلى طبيبك أو الصيدلي قبل تناول كبسولات إترازول.<br />أخبر طبيبك إذا كنت تتناول أي أدوية قبل استخدام كبسولات إترازول.<br />&bull; <strong>لا تستخدم كبسولات إترازول إذا كنت</strong> تتناول أي من الأدوية التالية، أو خال أسبوعين من التوقف عن<br />تناول إترازول:<br /><strong>الأدوية المستخدمة في علاج مشاكل القلب أو الدم أو الدورة الدموية</strong><br />- اليسكيرين، ابليرينون، ليركانديبين ,&nbsp;فيلوديبين أو نيسولديبين )لارتفاع ضغط الدم(<br />- بيبريديل، إيفابرادين أو رانولازين - )للذبحة الصدرية(<br />- دابيغاتران أو تيكاجريلور )لتجلط الدم(<br />- ديسوبيراميد، دوفيتيليد، درونيدارون أو كينيدين )لعدم انتظام ضربات القلب(<br />- لوميتابيد، لوفاستاتين أو سيمفاستاتين )لخفض الكوليسترول(<br />- سيلدينافيل )لعلاج ارتفاع ضغط الدم الشرياني الرئوي(.</p><table><tbody><tr><td>&nbsp; &nbsp; - فينيرينون (يستخدم لتقليل مخاطر مشاكل الكلى والقلب الخطيره</td></tr></tbody></table><p><strong>أدوية لعلاج مشاكل المعدة أو الإمساك</strong><br />- سيسابريد )لاضطرابات المعدة(<br />- دومبيريدون )لعلاج الغثيان والقيء(.<br />- نالوكسيغول )للإمساك الناجم عن تناول المسكنات الأفيونية(<br /><strong>أدوية لعلاج الصداع والنوم أو مشاكل الصحة العقلية</strong><br />- ثنائي هيدروإرغوتامين أو إرغوتامين )قلويدات الإرغوت المستخدمة في الصداع النصفي(<br />- ميدازولام )يؤخذ عن طريق الفم( أو تريازولام )للتهدئة أو لمساعدتك على النوم(.<br />- لوراسيدون، بيموزيد، كيتيابين أو سرتيندول )لمرض انفصام الشخصية، اضطراب ثنائي القطب أو مشاكل<br />الصحة العقلية الأخرى(</p><table><tbody><tr><td>- الميثادون (يستخدم لعلاج الألم المزمن، ويستخدم أي ًضا لعلاج<br />الإدمان على الهيروين أو المواد الأفيونية الأخرى</td></tr></tbody></table><p><strong>أدوية لعلاج مشاكل المسالك البولية</strong><br />- داريفيناسين )لعلاج سلس البول(<br />- فيزوتيرودين أو سوليفيناسين )لتهيج المثانة البولية( عند استخدامه في المرضى الذين يعانون من مشاكل<br />معينة في الكلى أو الكبد.<br /><strong>أدوية لعلاج الحساسية</strong><br />- أستيميزول، ميزولاستين أو تيرفينادين )للحساسية(.<br /><strong>أدوية لعلاج مشاكل الانتصاب والقذف</strong><br />- افانافيل )لعلاج ضعف الانتصاب(<br />- دابوكستين )لسرعة القذف(<br />- فاردينافيل )لعلاج ضعف الانتصاب( عند استخدامه للرجال الذين تزيد أعمارهم عن 75 عامًا<br /><strong>أدوية أخرى تحتوي على:</strong><br />- كولشيسين )للنقرس( عند استخدامه في المرضى الذين يعانون من مشاكل في الكلى أو الكبد<br />- إرغومترين )إرغونوفين( أو ميثيلرجومترين )ميثيلرجونوفين( قلويدات الإرغوت المستخدمة بعد الولادة<br />- إليغلوستات )لمرض جوشر( عند استخدامه في المرضى الذين لا يستطيعون تحليل بعض الأدوية في الجسم<br />- هالوفانترين )للملاريا(<br />- إيرينوتيكان )للسرطان(<br />- ايزافوكونازول )لعلاج الالتهابات الفطرية(.<br />- أومبيتاسفير، باريتابريفير، ريتونافير مع أو بدون داسابوفير - )لعلاج التهاب الكبد سي(</p><table><tbody><tr><td>- فوكلوسبورين (لعلاج التهاب الكلية الذئبي</td></tr></tbody></table><p style="text-indent:50px">تذكر - لا تتناول أي من الأدوية المذكورة أعلاه لمدة أسبوعين بعد آخر علاج لك باستخدام كبسولات إترازول.<br /><strong>توخ حذرًا خاصًا مع إترازول</strong><br />تحدث إلى طبيبك أو الصيدلي قبل تناول هذا الدواء:<br />&bull; إذا كان لديك مشاكل في الكلى. قد يلزم تغيير جرعتك من إترازول<br />&bull; إذا كنت تعاني من مشاكل في الكبد مثل اصفرار الجلد )اليرقان(. قد تحتاج جرعتك من كبسولات إترازول<br />إلى التغيير. إذا شعرت بنقص حاد في الشهية، وشعرت بالغثيان، وتقيّأت، وشعرت بالتعب غير المعتاد، أو<br />تعاني من آلام في المعدة، أو ضعف العضات، أو اصفرار الجلد أو بياض العينين، أو بول داكن بشكل غير<br />عادي، براز شاحب أو تساقط الشعر، توقف عن تناول كبسولات إترازول وأخبر طبيبك على الفور<br />&bull; إذا كان لديك في أي وقت مضى مشكلة في القلب بما في ذلك قصور القلب )وتسمى أيضًا قصور<br />القلب الاحتقاني أو CHF (. كبسولات إترازول يمكن أن تجعل الأمر أسوأ.<br />إذا عانيت بعد تناول هذا الدواء من أي مما يلي:<br />&bull; ضيق التنفس<br />&bull; زيادة غير متوقعة في الوزن<br />&bull; تورم في ساقيك أو بطنك<br />&bull; تشعر بتعب غير المعتاد<br />&bull; الاستيقاظ بضيق التنفس ليلاً<br />توقف عن تناول كبسولات إترازول وأخبر طبيبك على الفور. قد تكون هذه علامات على قصور القلب<br />&bull; إذا كنت مصابًا بمتلازمة نقص المناعة المكتسب )الإيدز( أو إذا كان جهازك المناعي لا يعمل كما ينبغي<br />&bull; إذا كنت قد عانيت من رد فعل تحسسي تجاه منتج آخر مضاد للفطريات في الماضي<br />&bull; إذا كان لديك تليف كيسي<br />إذا لم تكن متأكدًا مما إذا كان أي مما سبق ينطبق عليك، فتحدث إلى طبيبك أو الصيدلي قبل تناول<br />كبسولات إترازول.<br /><strong>الأطفال وكبار السن</strong><br />لا تُعطى كبسولات إترازول عادة للأطفال دون سن 12 عامًا أو كبار السن. ومع ذلك، قد يصفها طبيبك<br />في حالات خاصة.<br /><strong>تحاليل الدم</strong><br />إذا استمر استخدام كبسولات إترازول لأكثر من شهر، فقد يرغب طبيبك في فحص الكبد عن طريق فحص<br />دمك.<br /><strong>الأدوية الأخرى وكبسولات إترازول</strong><br />أخبر طبيبك أو الصيدلي إذا كنت تتناول أي أدوية أخرى، أو تناولت أي أدوية مؤخراً، أو قد تتناول أي أدوية<br />أخرى. ويشمل ذلك الأدوية التي تشتريها بدون وصفة طبية أو الأدوية العشبية.<br />هناك بعض الأدوية التي يجب عدم تناولها أثناء تناول كبسولات إترازول. تم سرد هذه الأدوية أعاه تحت<br />عنوان &quot;لا تستخدم كبسولات الإترازول إذا كنت:&quot;.<br />لا ينصح باستخدام بعض الأدوية مع كبسولات إترازول.<br />قد يقرر طبيبك أنه لا ينبغي عليك تناول بعض الأدوية في نفس الوقت، أو في خال أسبوعين من إيقاف<br />كبسولات إترازول.<br />ومن أمثلة هذه الأدوية:<br /><strong>أدوية لعلاج مشاكل القلب أو الدم أو الدورة الدموية</strong><br />- أبيكسابان، ريفاروكسابان أو فوراباكسار )لتجلط الدم(<br />- أتورفاستاتين )لخفض الكوليسترول(<br />- فيلوديبين )لارتفاع ضغط الدم(<br />- ريوسيجوات أو تادالافيل )لارتفاع ضغط الدم الرئوي(</p><table><tbody><tr><td>- فينيرينون (يستخدم لتقليل مخاطر مشاكل الكلى والقلب الخطيره</td></tr></tbody></table><p style="text-indent:50px"><br /><strong>أدوية لعلاج الصرع أو الصداع أو مشاكل الصحة العقلية</strong><br />- الفينيتوين أو الكاربامازيبين أو الفينوباربيتال )مضادات الصرع(<br />- إليتريبتان )لعلاج الصداع النصفي(<br />- نبتة سانت جون ) Hypericum, perforatum ( )دواء عشبي يستخدم لمشاكل الصحة العقلية(<br /><strong>أدوية لعلاج مشاكل المسالك البولية</strong><br />- تامسولوسين )لعلاج سلس البول عند الذكور(<br />- تولتيرودين )لتهيج المثانة البولية(.<br /><strong>أدوية لعلاج السرطان</strong><br />- أكسيتينيب، بوسوتينيب، كابازيتاكسيل، كابوزانتينيب، سيريتينيب، كوبيميتينيب، كريزوتينيب، دابرافينيب،<br />داساتينيب، دوسيتاكسيل، إيبروتينيب، لاباتينيب، نيلوتينيب، أولاباريب، بازوبانيب، ريجورافينيب، ترابزينب،<br />سونيتينيب ترابيكتيدين، تراستوزوماب إيمتانسين، موبوسيرتينيب, إنتريكتينيب أو القلويدات الفينكية )مثل فينفلونين، فينوريلبين(.<br /><strong>أدوية لعلاج السل</strong><br />- بيداكويلين، أيزونيازيد، ريفابوتين أو ريفامبيسين )لمرض السل(<br />أدوية لعلاج فيروس نقص المناعة البشرية ) HIV ( أو التهاب الكبد<br />- ايفافيرينز أو نيفيرابين )لفيروس نقص المناعة البشرية / الإيدز(<br />- إلباسفير / جرازوبريفير، سيميبريفير، تينوفوفير ألافيناميد فومارات )تاف(، تينوفوفير ديسوبروكسيل فومارات<br />TDF( ( )لفيروس نقص المناعة البشرية أو التهاب الكبد(<br />أدوية لعلاج السل<br />- بيداكويلين، أيزونيازيد، ريفابوتين أو ريفامبيسين )لمرض السل(<br /><strong>أدوية لعلاج فيروس نقص المناعة البشرية ) HIV ( أو التهاب الكبد</strong><br />- ايفافيرينز أو نيفيرابين )لفيروس نقص المناعة البشرية / الإيدز(<br />- إلباسفير / جرازوبريفير، سيميبريفير، تينوفوفير ألافيناميد فومارات )تاف(، تينوفوفير ديسوبروكسيل فومارات<br />TDF( ( )لفيروس نقص المناعة البشرية أو التهاب الكبد(<br /><strong>الأدوية المستخدمة بعد زراعة الأعضاء</strong><br />- إيفروليموس، رابامايسين )المعروف أيضًا باسم سيروليموس(، تيمسيروليموس<br /><strong>أدوية لعلاج تضخم البروستاتا الحميد</strong><br />- الفوزوسين، سيلودوسين<br /><strong>أدوية لعلاج مشاكل الرئة أو الحساسية</strong><br />- سيكليسونيد )للالتهابات والربو والحساسية(<br />- ايباستين )للحساسية(<br />- سالميتيرول )لعلاج الربو أو مرض الانسداد الرئوي المزمن - )COPD<br /><strong>أدوية لعلاج مشاكل الانتصاب والقذف</strong><br />- تادالافيل أو فاردينافيل )عند استخدامه للرجال بعمر 75 عامًا أو أقل( )لعلاج ضعف الانتصاب(<br /><strong>أدوية أخرى تحتوي على:</strong><br />- كولشيسين )للنقرس(<br />- فينتانيل )للألم(<br />- لوماكافتور / ايفاكافتور )للتليف الكيسي(</p><table><tbody><tr><td>- فوكلوسبورين (لعلاج التهاب الكلية الذئبي</td></tr></tbody></table><p style="text-indent:50px"><br /><br /><strong>تذكر - لا تتناول أي من الأدوية المذكورة أعاه لمدة أسبوعين بعد آخر عاج لك باستخدام كبسولات إترازول.</strong><br />هذه ليست قائمة كاملة، لذا أخبر طبيبك إذا كنت تتناول أو تخطط لتناول أي من هذه الأدوية، أو أي<br />أدوية أخرى.<br />يجب توخي الحذر عند استخدام كبسولات إترازول مع بعض الأدوية الأخرى.<br />قد تكون أكثر عرضة للإصابة بآثار جانبية، أو قد تحتاج جرعة إترازول أو الدواء الآخر إلى التغيير. ومن أمثلة<br />هذه الأدوية:<br />أدوية لعلاج مشاكل القلب أو الدم أو الدورة الدموية<br />- بوسنتان )لعلاج ارتفاع ضغط الدم الرئوي(<br />- حاصرات قنوات الكالسيوم مثل ديهيدروبيريدين مثل أملوديبين، إيزراديبين، نيفيديبين، نيموديبين أو ديلتيازيم<br />)لارتفاع ضغط الدم(<br />- أو فيراباميل )لارتفاع ضغط الدم(.<br />- سيلوستازول )لمشاكل الدورة الدموية(.<br />- &quot;الكومارين&quot; مثل الوارفارين )لتجلط الدم(<br />- الديجوكسين )للرجفان الأذيني(<br />- نادولول )لارتفاع ضغط الدم الرئوي أو الذبحة الصدرية(<br /><strong>أدوية لعلاج مشاكل المعدة أو الإسهال</strong><br />- أبريبتانت أو نيتوبيتانت )للغثيان والقيء أثناء علاج السرطان(<br />- لوبيراميد )للإسهال(.<br />- مضادات الحموضة مثل الألومنيوم والكالسيوم والمغنيسيوم وبيكربونات الصوديوم ؛ مضادات مستقبلات<br />H2 مثل السيميتيدين، الرانيتيدين ومثبطات مضخة البروتون مثل لانزوبرازول، أوميبرازول، رابيبرازول )لعاج<br />مشاكل حمض المعدة(<br /><strong>أدوية لعلاج مشاكل النوم أو مشاكل الصحة العقلية</strong><br />- ألبرازولام، بروتيزولام، بوسبيرون، أو ميدازولام )عند حقنه في الوريد( )للقلق أو لمساعدتك على النوم(<br />- زوبيكلون )لمساعدتك على النوم(<br />- ريبوكستين أو فينلافاكسين )لعلاج الاكتئاب والقلق(.<br />- أريبيبرازول، كاريبرازين، هالوبيريدول أو ريسبيريدون )لمرض انفصام الشخصية، اضطراب ثنائي القطب أو<br />مشاكل الصحة العقلية الأخرى(<br />- جالانتامين )لمرض الزهايمر(<br />- جوانفاسين )لعلاج اضطراب فرط الحركة ونقص الانتباه(<br /><strong>أدوية لعلاج مشاكل المسالك البولية</strong><br />- إيميدافيناسين، فيزوتيرودين، أوكسيبوتينين، سوليفيناسين )للمثانة البولية المتهيجة(<br /><strong>أدوية لعلاج السرطان</strong><br />- بورتيزوميب، برنتوكسيماب فيدوتين بوسولفان، إرلوتينيب، جيفيتينيب، إدياليسيب، إيماتينيب، نينتيدانيب،<br />بانوبينوستات، بوناتينيب، روكسوليتينيب أو سونيدجيب<br />أدوية لعلاج العدوى<br />- سيبروفلوكساسين أو كلاريثروميسين أو إريثروميسين )للالتهابات البكتيرية(<br />&minus;ديلامانيد )لمرض السل(<br />- أرتيميثير - لوميفانترين أو كينين )لعلاج الملاريا(<br />- برازيكوانتيل )لديدان فلوك والديدان الشريطية(<br /><strong>أدوية لعلاج فيروس نقص المناعة البشرية ) HIV ( أو التهاب الكبد</strong><br />- كوبيسيستات، إلفيتيجرافير المعزز، مارافيروك، ريتونافير، بدارونافيرالمعزز بالريتونافير، بفوسامبرينافيرالمعزز<br />بالريتونافير، إندينافير أو ساكوينافير )لفيروس نقص المناعة البشرية(<br />- جليكابريفير / بيبرنتاسفير )لالتهاب الكبد)</p><p><strong>الأدوية المستخدمة بعد زراعة الأعضاء</strong><br />- سيكلوسبورين أو تاكروليموس<br /><strong>أدوية لعلاج تضخم البروستاتا الحميد</strong><br />- دوتاستيريد<br /><strong>أدوية لعلاج مشاكل الرئة أو الحساسية أو الأمراض الالتهابية</strong><br />- بلاستين، أو روباتادين )للحساسية(<br />- ميثيل بريدنيزولون أو ديكساميثازون )الأدوية التي تُعطى عن طريق الفم أو الحقن للربو أو الحساسية أو<br />الحالات الالتهابية(<br />- بوديزونيد أو فلوتيكاسون )لعلاج الربو والحساسية(.<br /><strong>أدوية لعلاج مشاكل الانتصاب والقذف</strong><br />- سيلدينافيل )لعلاج ضعف الانتصاب(<br /><strong>أدوية لعلاج الآلام</strong><br />- الفنتانيل، البوبرينورفين، أوكسيكودون أو سوفنتانيل )للألم(<br />- ميلوكسيكام )لالتهاب المفاصل وآلامها(.<br /><strong>أدوية أخرى تحتوي على:</strong><br />- أليتريتينوين )عن طريق الفم( )للإكزيما(.<br />- كابيرجولين )لمرض باركنسون(<br />- المنتجات التي تحتوي على القنب بما في ذلك الأدوية )مثل الغثيان والقيء أو التشنجات العضلية لدى<br />مرضى التصلب المتعدد(<br />- سيناكالسيت )لعلاج فرط نشاط الغدة الجار درقية(<br />- دينوجيست أو يوليبريستال )موانع الحمل(<br />- إيليجلوستات )لمرض جوشر( عند استخدامه في المرضى الذين لا يستطيعون تحليل بعض الأدوية في الجسم<br />- إيفاكافتور )لعلاج التليف الكيسي(<br />- ليفاسيتيل ميثادول وميثادون )لعلاج إدمان المخدرات(<br />- ريباجلينيد أو ساكساجليبتين )لمرض السكري(<br />هذه ليست قائمة كاملة، لذا أخبر طبيبك إذا كنت تتناول أو تخطط لتناول أي من هذه الأدوية، أو أي أدوية<br />أخرى. قد يحتاجون إلى تغيير قد يحتاجون إلى تغيير جرعة إترازول أو الأدوية الأخرى الخاصة بك.<br /><strong>الحمل</strong><br />لا تتناولي إترازول إذا كنتِ حاما، يجب على السيدات في سن الحمل واللاتي قد يُصبحن حوامل استخدام<br />وسيلة مناسبة لمنع الحمل؛ لضمان عدم حدوث الحمل أثناء العاج بإترازول.<br />يجب الاستمرار في استخدام وسائل منع الحمل خال أول دورة شهرية عادية بعد وقف العاج بالإترازول،<br />حيث إن الدواء قد يظل في الجسم لبعض الوقت.<br /><strong>الرضاعة الطبيعية</strong><br />أبلغي الطبيب الخاص بك إذا كنت تمارسين الرضاعة الطبيعية، وتم وصف إترازول لكِ، فقد تتواجد كمية<br />صغيرة من الدواء في اللبن.<br />استشيري الطبيب أو الصيدلي الخاص بكِ قبل تناول أي دواء.<br />تناول إترازول مع الطعام والشراب<br />يجب تناول إترازول بعد الوجبات مباشرة، للحصول على أقصى امتصاص للدواء.<br /><strong>القيادة واستخدام الآلات</strong><br />لم يتم إجراء أية دراسات بشأن التأثيرات على القيادة واستخدام الآلات.<br />معلومات هامة عن أحد مكونات إترازول<br />يحتوي هذا الدواء على سكر السكروز، إذا كان الطبيب الخاص بك قد أخبرك بأنك لا تتحمل بعض أنواع<br />السكريات، فاتصل به قبل تناول الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>تناول إترازول دائمًا كما أخبرك الطبيب الخاص بك بالضبط. يجب مراجعة الطبيب أو الصيدلي الخاص بك إذا لم تكن متـأكدًا.</p><p>أسلوب وطريقة التناول ومدة العلاج</p><p>سيعتمد عدد مرات التناول ومدة العلاج علي نوع الفطريات ومكان العدوي، سيخبرك الطبيب الخاص بك بالضبط بالجرعة التي يجب تناولها.</p><p>يحتوي الجدول التالي علي قائمة ببعض الجرعات شائعة الاستخدام :</p><p><img alt="" width="609" height="396" src="data:image/png;base64,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" /></p><p><img alt="" width="611" height="214" src="data:image/png;base64,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" /></p><p>متي يجب عليك توقع نتائج العلاج</p><p>تأثير الدواء لا يحدث في الحال.</p><p>في عدوي الجلد، تختفي إصابات الجلد عادةً بعد وقف العلاج ببضعة أسابيع. هذه أحد خصائص عدوي الفطريات، حيث يزيل الدواء الفطريات ولكن تبقي الإصابات الجلدية حتي ينمو جلد جديد.</p><p>ستختفي إصابات الظفر بعد 6-9 أشهر من العلاج، حيث إن الدواء سيقضي علي الفطريات ، ولكن نمو ظفر جديد يستغرق عدة أشهر.</p><p>لا تقلق إذا لم تلاحظ تحسنًا أثناء العلاج.</p><p>فسيظل الدواء بأظافرك لعدة أشهر وهو يقوم بعمله.</p><p>أوقف العلاج بمجرد أن يخبرك الطبيب الخاص بك بذلك، حتي إذا لم تكن تري أية علامات واضحة علي التحسن.</p><p>قد تتطلب العدوي بالأعضاء الداخلية جرعات أعلي والعلاج لفترات أطول.</p><p>لا تنسي تناول دوائك.</p><p>التزم بهذه التعليمات، ما لم يخبرك الطبيب الخاص بك بخلاف ذلك.</p><p>سيخبرك الطبيب الخاص بك بالمدة التي يجب عليك تناول إترازول خلالها.</p><p>لا توقف العلاج قبل أن ينصحك الطبيب الخاص بك بذلك . وإلا فلن يكون العلاج كاملا.</p><p><strong>&nbsp;إذا تناولت كمية من إترازول أكثر مما يجب</strong></p><p>اتصل بالطبيب أو الصيدلي الخاص بك علي الفور إذا تناولت كمية من إترازول أكثر مما يجب.</p><p><strong>إذا نسيت تناول إترازول</strong></p><p>تناول الجرعة التي نسيتها، بمجرد تذكرك لها . ومع ذلك ، إذا كان قد حان موعد الجرعة التالية تقريبًا. فتخطي الجرعة التي نسيتها، واستمر في تناول الجرعات وفقًا للجدول المعتاد. لا تتناول جرعة مضاعفة لتعويض الجرعة التي نسيتها.</p><p>إذا كانت لديك أية أسئلة إضافية حول استخدام هذا الدواء ، اسأل الطبيب أو الصيدلي الخاص بك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>مثله مثل كافة الأدوية ، قد يُسبب إترازول أعراضًا جانبية، علي الرغم من عدم حدوثها لدي الجميع. من الممكن حدوث الأعراض الجانبية التالية:</p><p><strong>شائعة (تُؤثر على عدد من 1 إلى 10 مستخدمين من كل 100 مستخدم):</strong></p><p>●&nbsp; اضطراب أو ضعف بحاسة التذوق</p><p><strong>غير شائعة (تُؤثؤ علي: 1 إلى 10 مستخدمين في كل 1.000 مستخدم):</strong></p><p>●&nbsp; التهاب الكبد، يرقان (اصفرار)</p><p>●&nbsp; تورم موضعي (وذمة)</p><p><strong>نادرة جدًا (تؤثر علي أقل من مستخدم واحد من كل 10.000 مستخدم):</strong></p><p>●&nbsp; انخفاض غدد خلايا الدم البيضاء (قلة كريات الدم البيضاء، قلة خلايا العدلات)</p><p>●&nbsp; انخفاض عدد الصفائح الدموية (قلة الصفائح الدموية)</p><p>●&nbsp; تفاعلات حساسية شديدة</p><p>●&nbsp; انخفاض ملحوظ للبوتاسيوم في الدم (نقص البوتاسيوم بالدم)</p><p>●&nbsp; زيادة الدهون الثلاثية (أحد أنواع الدهون) في الدم (فرط الدهون الثلاثية)</p><p>●&nbsp; صداع، دوخة</p><p>●&nbsp; ألم، فقدان الإحساس ، وعدم القدرة علي التحكم في العضلات</p><p>●&nbsp; اضطرابات بصرية، بما في ذلك عدم وضوح أو ازدواج الرؤية</p><p>●&nbsp; رنين بالأذن (طنين الأذن)</p><p>●&nbsp; ألم في البطن، قئ، غثيان، إسهال، إحساس بأمتلاء غير مريح بعد الوجبات (عُسٌرُ الهَضم).إمساك</p><p>●&nbsp; ارتفاع إنزيمات الكبد</p><p>●&nbsp; طفح جلدي، حكة، أمراض جلدية شديدة، تساقط الشعر، ازدياد الحساسية لضوء الشمس.</p><p>●&nbsp; ضعف عضلي، آلام بالعضلات و المفاصل</p><p>●&nbsp; تكرار التبول أثناء فتره النهار، وسلس البول (هروب أو تسرب البول)</p><p>●&nbsp; اضطرابات الدورة الشهرية، عدم القدرة علي الانتصاب</p><p><strong>غير معروفة (لا يمكن تقدير تكرار الأعراض الجانبية من واقع البيانات المتاحة):</strong></p><p>●&nbsp; تفاعلات حساسية</p><p>●&nbsp; خدر ووخز (اضطرابات بالإحساس) ، فقدان الحساسية للألم أو اللمس (تدني الإحساس)</p><p>●&nbsp; فقدان قدرة القلب علي ضخ الدم بكفاءة (هبوط/ فشل القلب الاحتقاني)</p><p>●&nbsp; تراكم غير طبيعي للسوائل في الرئتين، مما يؤدي إلي تورم (وذمة رئوية)</p><p>●&nbsp; سمية (تسمم) الكبد، فشل كبدي حاد</p><p>يُرجي إبلاغ الطبيب أو الصيدلي الخاص بك إذا أصبحت أي من الأعراض الجانبية خطيرة ، أو أية أعراض جانبية غير مدرجة في هذة النشرة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>يحفظ بعيدًا عن متناول ورؤية الأطفال.</p><p>يحفظ في درجة حرارة أقل من ٢٥ درجة مئوية.</p><p>لا تَستخدَم إترازول بعد انتهاء تاريخ الصلاحية المدون علي العبوة. يُشير تاريخ انتهاء الصلاحية إلي آخر يوم من ذلك الشهر.</p><p>يجب عدم التخلص من الأدوية عن طريق مياه الصرف أو مع المخالفات المنزلية. استشر الصيدلي الخاص بك عن كيفية التخلص من الأدوية التي لم تعد الحاجة إليها. ستساعد هذه الإجراءات في حماية البيئة</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>●&nbsp; المادة الفعالة هي إتراكونازول. تحتوي كل كبسولة علي 100 ملج إتراكونازول</p><p>&bull; المكونات الأخرى هي:&nbsp;هيبروميللوز، بولوكسامير، سكروز، نشا الذرة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p style="text-indent:50px">يوجد إترازول داخل كبسولات ذات اللون الوردي والتركوازي مكتوب عليها&nbsp;SJ153، تحتوي كل كبسولة على ١٠٠ ملج إتراكونازول في شكل حبيبات&nbsp;تحتوي العبوة على ٤ أو ١٥ كبسولة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>ساجا الصيدلانية</p><p>الشركة العربية السعودية اليابانية للمنتجات الصيدلانية المحدودة</p><p>جدة &ndash; المملكة العربية السعودية</p><p><strong>-للإبلاغ عن أية آثار جانبية</strong></p><p><strong>&bull;&nbsp;المملكة العربية السعودية</strong></p><p>- المركز الوطني للتيقظ والسلامة الدوائية</p><p>- مركز اتصال هيئة الغذاء والدواء : ١٩٩٩٩</p><p>- البريد الإلكتروني: npc.drug@sfda.gov.sa</p><p>- الموقع الإلكتروني:&nbsp;https://ade.sfda.gov.sa</p><p><strong>&bull;&nbsp;دول الخليج الأخرى/ الدول الأخرى</strong></p><p>- الرجاء الاتصال بالمؤسسات والهيئات الوطنية في كل دولة</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            يناير/٢٠٢٤
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                ITRAZOL® 100mg Capsules
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                ITRAZOL in pink and turquoise capsules coded by SJ153, each capsule contain 100 mg Itraconazole in a pellet formulation
For a full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hard Gelatin Capsules
Capsule: Opaque turquoise cap and pink transparent body.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>1.&nbsp; Vulvovaginal candidosis</p><p>2.&nbsp; Pityriasis versicolor</p><p>3.&nbsp; Dermatophytoses caused by organisms susceptible to itraconazole</p><p>4.&nbsp; Oral candidosis</p><p>5.&nbsp; Fungal keratitis</p><p>6.&nbsp; Systemic mycoses</p><p>7.&nbsp; Onychomycosis</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>ITRAZOL&reg; is for oral administration and must be taken immediately after a meal for maximal absorption. The capsules must be swallowed whole.</p><p>Treatment schedules in adults for each indication are as follows:</p><p><em>Short-Term Usage</em></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Indication</strong></p></td><td style="vertical-align:top"><p><strong>Dose</strong></p></td></tr><tr><td style="vertical-align:top"><p>Vulvovaginal candidosis</p></td><td style="vertical-align:top"><p>200 mg twice daily for 1 day or 200 mg once daily for 3 days.</p></td></tr><tr><td style="vertical-align:top"><p>Pityriasis versicolor</p></td><td style="vertical-align:top"><p>200 mg once daily for 7 days</p></td></tr><tr><td style="vertical-align:top"><p>Tinea corporis, tinea cruris</p></td><td style="vertical-align:top"><p>100 mg once daily for 2 weeks or 200 mg once daily for 7 days</p></td></tr><tr><td style="vertical-align:top"><p>Tinea pedis, tinea manuum</p></td><td style="vertical-align:top"><p>100 mg once daily for 4 weeks</p></td></tr><tr><td style="vertical-align:top"><p>Oral candidosis</p></td><td style="vertical-align:top"><p>100 mg once daily for 2 weeks</p></td></tr><tr><td style="vertical-align:top"><p>Fungal keratitis</p></td><td style="vertical-align:top"><p>200 mg once daily for 3 weeks</p></td></tr></tbody></table><p>Treatment should not exceed 4 weeks.</p><p><em>Long Term Usage</em></p><p>Dosage recommendations vary according to the infection treated.</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Indication</strong></p></td><td style="vertical-align:top"><p><strong>Dose</strong></p></td><td style="vertical-align:top"><p><strong>Median Duration</strong></p></td></tr><tr><td style="vertical-align:top"><p>Onychomycosis</p></td><td style="vertical-align:top"><p>200 mg od</p></td><td style="vertical-align:top"><p>3 months</p></td></tr><tr><td style="vertical-align:top"><p>Aspergillosis</p></td><td style="vertical-align:top"><p>200 mg od</p></td><td style="vertical-align:top"><p>2-5 months</p></td></tr><tr><td style="vertical-align:top"><p>Candidosis</p></td><td style="vertical-align:top"><p>100-200 mg od</p></td><td style="vertical-align:top"><p>3 weeks - 7 months</p></td></tr><tr><td style="vertical-align:top"><p>Non-meningeal cryptococcosis</p></td><td style="vertical-align:top"><p>200 mg od</p></td><td style="vertical-align:top"><p>1-6 months</p></td></tr><tr><td style="vertical-align:top"><p>Cryptococcal meningitis</p></td><td style="vertical-align:top"><p>200 mg bid</p></td><td style="vertical-align:top"><p>2 months - 1 year</p></td></tr><tr><td style="vertical-align:top"><p>Histoplasmosis</p></td><td style="vertical-align:top"><p>200 mg od - 200 mg bid</p></td><td style="vertical-align:top"><p>8 months</p></td></tr><tr><td style="vertical-align:top"><p>Sporotrichosis</p></td><td style="vertical-align:top"><p>100 mg od</p></td><td style="vertical-align:top"><p>3 months</p></td></tr><tr><td style="vertical-align:top"><p>Paracoccidioidomycosis</p></td><td style="vertical-align:top"><p>100 mg od</p></td><td style="vertical-align:top"><p>6 months</p></td></tr><tr><td style="vertical-align:top"><p>Chromomycosis</p></td><td style="vertical-align:top"><p>100-200 mg od</p></td><td style="vertical-align:top"><p>6 months</p></td></tr><tr><td style="vertical-align:top"><p>Blastomycosis</p></td><td style="vertical-align:top"><p>100 mg od - 200 mg bid</p></td><td style="vertical-align:top"><p>6 months</p></td></tr></tbody></table><p><em>Use in Children (below 12 years):</em></p><p>&nbsp;</p><p>Clinical data on the use of ITRAZOL&reg; capsules in paediatric patients are limited. ITRAZOL&reg; capsules should not be used in children unless the potential benefit outweighs the potential risks. (See Section 4.4)</p><p><em>Use in Elderly:</em></p><p>As for use in children</p><p>Use in patients with renal impairment:</p><p>Limited data are available on the use of oral itraconazole in patients with renal impairment. Caution should be exercised when this drug is administered in this patient population.</p><p>Use in patients with hepatic impairment:</p><p>Limited data are available on the use of oral itraconazole in patients with hepatic impairment. Caution should be exercised when this drug is administered in this patient population. (See Section 5.2).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                ITRAZOL® capsules are contra-indicated in patients with known hypersensitivity to itraconazole or to any of the excipients.
Coadministration of a number of CYP3A4 substrates is contraindicated with ITRAZOL® Capsules (see sections 4.4 and 4.5). These include:


Analgesics; Anaesthetics
Methadone	
Ergot alkaloids (e.g. dihydroergotamine, ergometrine, ergotamine, methylergometrine)
Anti-bacterials for Systemic Use; Anti-mycobacterials; Antimycotics for Systemic Use
Isavuconazole
Anthelmintics; Antiprotozoals
Halofantrine
Antihistamines for Systemic Use
Astemizole	Mizolastine	Terfenadine
Antineoplastic Agents
Irinotecan
Antithrombotic Agents
Dabigatran	Ticagrelor
Antivirals for Systemic Use
Ombitasvir/Paritaprevir/Ritonavir (with or without Dasabuvir)
Cardiovascular System (Agents Acting on the Renin-Angiotensin System; Antihypertensives; Beta Blocking Agents; Calcium Channel Blockers; Cardiac Therapy; Diuretics)
Felodipine*
Finerenone
Aliskiren	Dronedarone	Nisoldipine
Bepridil	Eplerenone	Quinidine
Disopyramide	Ivabradine	Ranolazine
Dofetilide	Lercanidipine	Sildenafil (pulmonary hypertension)
 
Gastrointestinal Drugs, including Antidiarrheals, Intestinal Anti-
inflammatory/Anti-infective Agents; Antiemetics and Antinauseants; Drugs for Constipation; Drugs for Functional Gastrointestinal Disorders
Cisapride	Domperidone	Naloxegol
Lipid Modifying Agents
Lovastatin	Lomitapide	Simvastatin
	Immunosuppressants	
	Voclosporin	
Psychoanaleptics; Psycholeptics (eg, antipsychotics, anxiolytics, and hypnotics)
Lurasidone	Pimozide	Sertindole
Midazolam (oral)	Quetiapine	Triazolam
Urologicals
Avanafil	Darifenacin	Solifenacin (in patients with severe renal impairment or moderate
to severe hepatic impairment)
Dapoxetine	Fesoterodine (in patients with moderate or severe renal or hepatic impairment)	Vardenafil (in patients older than 75 years)
Miscellaneous Drugs and Other Substances
Colchicine (in patients with renal or hepatic impairment)	Eliglustat (in patients that are CYP2D6 poor metabolisers (PM), CYP2D6 intermediate metabolisers (IMs) or extensive metabolisers (EMs) that are taking a strong or moderate CYP2D6 inhibitor)

*Based on clinical drug interaction information with itraconazole

Increased plasma concentrations of these drugs, caused by coadministration with itraconazole, may increase or prolong both therapeutic and adverse effects to such an extent that a potentially serious situation may occur. For example, increased plasma concentrations of some of these drugs can lead to QT prolongation and ventricular tachyarrhythmias including occurrences of torsade de pointes, a potentially fatal arrhythmia. Specific examples are listed in section 4.5 Interaction with other medicinal products and other forms of interaction
ITRAZOL® capsules should not be administered to patients with evidence of ventricular dysfunction such as congestive heart failure (CHF) or a history of CHF except for the treatment of life-threatening or other serious infections. See Section 4.4
ITRAZOL® capsules must not be used during pregnancy (except for life-threatening cases). See section 4.6.
Women of childbearing potential taking ITRAZOL® should use contraceptive precautions. Effective contraception should be continued until the menstrual period following the end of ITRAZOL® therapy.
Coadministration with venetoclax is contraindicated in patients with CLL/SLL during the dose initiation and ramp-up phase of venetoclax due to the potential for an increased risk of tumor lysis syndrome.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em><u>Cross-hypersensitivity</u></em></p><p>There is no information regarding cross-hypersensitivity between itraconazole and other azole antifungal agents. Caution should be used in prescribing ITRAZOL&reg; capsules to patients with hypersensitivity to other azoles.</p><p>&nbsp;</p><p><em><u>Cardiac effects</u></em></p><p>In a healthy volunteer study with ITRAZOL&reg; IV, a transient asymptomatic decrease of the left ventricular ejection fraction was observed; this resolved before the next infusion. The clinical relevance of these findings to the oral formulations is unknown. Itraconazole has been shown to have a negative inotropic effect and ITRAZOL&reg; has been associated with reports of congestive heart failure. Heart failure was more frequently reported among spontaneous reports of 400 mg total daily dose than among those of lower total daily doses, suggesting that the risk of heart failure might increase with the total daily dose of itraconazole.</p><p>ITRAZOL&reg; should not be used in patients with congestive heart failure or with a history of congestive heart failure unless the benefit clearly outweighs the risk. This individual benefit/risk assessment should take into consideration factors such as the severity of the indication, the dosing regimen (e.g. total daily dose), and individual risk factors for congestive heart failure. These risk factors include cardiac disease, such as ischaemic and valvular disease; significant pulmonary disease, such as chronic obstructive pulmonary disease; and renal failure and other oedematous disorders. Such patients should be informed of the signs and symptoms of congestive heart failure, should be treated with caution, and should be monitored for signs and symptoms of congestive heart failure during treatment; if such signs or symptoms do occur during treatment, ITRAZOL&reg; should be discontinued.</p><p>Calcium channel blockers can have negative inotropic effects which may be additive to those of itraconazole. In addition, itraconazole can inhibit the metabolism of calcium channel blockers. Therefore, caution should be used when co-administering itraconazole and calcium channel blockers due to an increased risk of CHF (see Section 4.5).</p><p><em>Hepatic effects</em></p><p>Very rare cases of serious hepatotoxicity, including some cases of fatal acute liver failure, have occurred with the use of ITRAZOL&reg;. Most of these cases involved patients who, had pre-existing liver disease, were treated for systemic indications, had significant other medical conditions and/or were taking other hepatotoxic drugs. Some patients had no obvious risk factors for liver disease. Some of these cases were observed within the first month of treatment, including some within the first week. Liver function monitoring should be considered in patients receiving ITRAZOL&reg; treatment. Patients should be instructed to promptly report to their physician signs and symptoms suggestive of hepatitis such as anorexia, nausea, vomiting, fatigue, abdominal pain or dark urine. In these patients treatment should be stopped immediately and liver function testing should be conducted. In patients with raised liver enzymes or active liver disease, or who have experienced liver toxicity with other drugs, treatment should not be started unless the expected benefit exceeds the risk of hepatic injury. In such cases liver enzyme monitoring is necessary.</p><p><em><u>Reduced gastric acidity</u></em></p><p>Absorption of itraconazole from ITRAZOL&reg; capsules is impaired when gastric acidity is reduced. In patients also receiving acid neutralising medicines (eg aluminium hydroxide), these should be administered at least 2 hours after the intake of ITRAZOL&reg; capsules. In patients with achlorhydria such as certain AIDS patients and patients on acid secretion suppressors (eg H2-antagonists, proton pump inhibitors), it is advisable to administer ITRAZOL&reg; capsules with a cola beverage.</p><p><em><u>Use in children</u></em></p><p>&nbsp;</p><p>Clinical data on the use of ITRAZOL&reg; capsules in paediatric patients is limited. ITRAZOL&reg; capsules should not be used in paediatric patients unless the potential benefit outweighs the potential risks.</p><p><em>Use in elderly</em></p><p>Clinical data on the use of ITRAZOL&reg; capsules in elderly patients is limited. ITRAZOL&reg; capsules should not be used in these patients unless the potential benefit outweighs the potential risks.</p><p><em><u>Hepatic impairment</u></em></p><p>Limited data are available on the use of oral itraconazole in patients with hepatic impairment. Caution should be exercised when the drug is administered in this patient population. (See Section 5.2)</p><p><em><u>Renal impairment</u></em></p><p>Limited data are available on the use of oral itraconazole in patients with renal impairment. Caution should be exercised when this drug is administered in this patient population. The oral bioavailability of itraconazole may be lower in patients with renal insufficiency. Dose adaptation may be considered.</p><p><em><u>Hearing Loss</u></em></p><p>Transient or permanent hearing loss has been reported in patients receiving treatment with itraconazole. Several of these reports included concurrent administration of quinidine which is contraindicated (see Section 4.3 Contraindications and 4.5 Interaction with other medicinal products and other forms of interaction, 3.Effect of itraconazole on the metabolism of other drugs). The hearing loss usually resolves when treatment is stopped, but can persist in some patients.</p><p><em><u>Immunocompromised patients</u></em></p><p>In some immunocompromised patients (e.g. neutropenic, AIDS or organ transplant patients), the oral bioavailability of ITRAZOL&reg; capsules may be decreased.</p><p><em><u>Patients with immediately life-threatening systemic fungal infections</u></em></p><p>Due to the pharmacokinetic properties (see section 5.2), ITRAZOL&reg; capsules are not recommended for initiation of treatment with immediately life-threatening systemic fungal infections.</p><p><em><u>Patients with AIDS</u></em></p><p>In patients with AIDS having received treatment for a systemic fungal infection such as sporotrichosis, blastomycosis, histoplasmosis or cryptococcosis (meningeal and non-meningeal) and who are considered at risk for relapse, the treating physician should evaluate the need for a maintenance treatment.</p><p><em><u>Neuropathy</u></em></p><p>If neuropathy occurs that may be attributable to ITRAZOL&reg; capsules, the treatment should be discontinued.</p><p><em>Disorders of Carbohydrate Metabolism</em></p><p>Patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine.</p><p><em>Cross-resistance</em></p><p>In systemic candidosis, if fluconazole-resistant strains of <em>Candida </em>species are suspected, it cannot be assumed that these are sensitive to itraconazole, hence their sensitivity should be tested before the start of itraconazole therapy.</p><p><em><u>Interaction potential</u></em></p><p><em>&nbsp;</em></p><p><strong>Coadministration of specific drugs with itraconazole may result in changes in efficacy of itraconazole and/or the coadministered drug, life-threatening effects and/or sudden death. Drugs that are contraindicated, not recommended or recommended for use with caution in combination with itraconazole are listed in section 4.3 Contraindications and section 4.5 Interaction with other medicinal products and other forms of interaction.</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Itraconazole is mainly metabolised through CYP3A4. Other substances that either share this metabolic pathway or modify CYP3A4 activity may influence the pharmacokinetics of itraconazole. Itraconazole is a strong CYP3A4 inhibitor and, a P-glycoprotein inhibitor and Breast Cancer Resistance Protein (BCRP) inhibitor.</strong></p><p><strong>Itraconazole may modify the pharmacokinetics of other substances that share this metabolic or these protein transporter pathways. Examples of drugs that may impact on the plasma concentration of itraconazole are presented by drug class in Table 1 below. Examples of drugs that may have their plasma concentrations impacted by itraconazole are presented in Table 2 below.</strong></p><p><strong>Due to the number of interactions, the potential changes in safety or efficacy of the interacting drugs are not included. Please refer to the prescribing information of the interacting drug for more information.</strong></p><p><strong>The interactions described in these tables are categorised as contraindicated, not recommended or to be used with caution with itraconazole taking into account the extent of the concentration increase and the safety profile of the interacting drug (see also sections 4.3 and 4.4 for further information). The interaction potential of the listed drugs was evaluated based on human pharmacokinetic studies with itraconazole, and/or human pharmacokinetic studies with other strong CYP3A4 inhibitors (e.g. ketoconazole) and/or in vitro data:</strong></p><p><strong>&nbsp;</strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>&lsquo;Contraindicated&rsquo;: Under no circumstances is the drug to be co-administered with itraconazole, and up to two weeks after discontinuation of treatment with itraconazole.</strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Not recommended&rsquo;: The use of the drug should be avoided during and up to two weeks after discontinuation of treatment with itraconazole, unless the benefits outweigh the potentially increased risks of side effects. If co-administration cannot be avoided, clinical monitoring for signs or symptoms of increased or prolonged effects or side effects of the concomitantly administered drug is recommended, and its dosage be reduced or</strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>interrupted as deemed necessary. When appropriate, it is recommended that plasma concentrations of the co-administered drug be measured.</strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>&lsquo;Use with caution&rsquo;: Careful monitoring is recommended when the drug is co-administered with itraconazole. Upon co-administration, it is recommended that patients be monitored closely for signs or symptoms of increased or prolonged effects or side effects of the interacting drug, and its dosage be reduced as deemed necessary. When appropriate, it is recommended that plasma concentrations of the co-administered drug be measured.</strong></p><p><strong>The interactions listed in these tables have been characterised in studies that were performed with recommended doses of itraconazole. However, the extent of interaction may be dependent on the dose of itraconazole administered. A stronger interaction may occur at a higher dose or with a shorter dosing interval. Extrapolation of the findings with other dosing scenarios or different drugs should be done with caution.</strong></p><p><strong>Once treatment is stopped, itraconazole plasma concentrations decrease to an almost undetectable concentration within 7 to 14 days, depending on the dose and duration of treatment. In patients with hepatic cirrhosis or in subjects receiving CYP3A4 inhibitors, the decline in plasma concentrations may be even more gradual. This is particularly important when initiating therapy with drugs whose metabolism is affected by itraconazole. (see section 5.2).</strong></p><p><strong>&nbsp;</strong></p><p><strong><u>Table 1: Examples of drugs that may impact the plasma concentration of itraconazole,</u></strong><strong> </strong><strong><u>presented by drug class</u></strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Medicinal products Per Oral [PO] Single Dose unless otherwise stated) within class</strong></p></td><td style="vertical-align:top"><p><strong>Expected/Potential effect on itraconazole levels (&uarr; = increase; &harr;</strong></p><p><strong>= no change; &darr; = decrease)</strong></p></td><td style="vertical-align:top"><p><strong>Clinical comment (see above for additional info and also sections 4.3 and 4.4)</strong></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Anti-bacterials for Systemic Use; Anti-mycobacterials</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Isoniazid</strong></p></td><td style="vertical-align:top"><p><strong>Although not studied directly, isoniazid is likely to decrease the concentrations of itraconazole</strong></p></td><td style="vertical-align:top"><p><strong>Not recommended</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Rifampicin PO 600 mg OD</strong></p></td><td style="vertical-align:top"><p><strong>Itraconazole AUC &darr;</strong></p></td><td style="vertical-align:top"><p><strong>Not recommended</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Rifabutin PO 300 mg OD</strong></p></td><td style="vertical-align:top"><p><strong>Itraconazole Cmax &darr; 71%, AUC &darr; 74%</strong></p></td><td style="vertical-align:top"><p><strong>Not recommended</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Ciprofloxacin PO 500 mg BID</strong></p></td><td style="vertical-align:top"><p><strong>Itraconazole Cmax &uarr; 53%, AUC &uarr; 82%</strong></p></td><td style="vertical-align:top"><p><strong>Use with caution</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Erythromycin 1 g</strong></p></td><td style="vertical-align:top"><p><strong>Itraconazole Cmax &uarr; 44%, AUC &uarr; 36%</strong></p></td><td style="vertical-align:top"><p><strong>Use with caution</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Clarithromycin PO 500 mg BID</strong></p></td><td style="vertical-align:top"><p><strong>Itraconazole Cmax &uarr; 90%, AUC &uarr; 92%</strong></p></td><td style="vertical-align:top"><p><strong>Use with caution</strong></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Antiepileptics</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Carbamazepine, Phenobarbital</strong></p></td><td style="vertical-align:top"><p><strong>Although not studied directly, these drugs are likely to decrease concentrations of</strong></p><p><strong>itraconazole</strong></p></td><td style="vertical-align:top"><p><strong>Not recommended</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Phenytoin PO 300 mg OD</strong></p></td><td style="vertical-align:top"><p><strong>Itraconazole Cmax &darr; 83%, AUC &darr; 93%</strong></p><p><strong>Hydroxyitraconazole Cmax &darr; 84%,</strong></p><p><strong>AUC &darr; 95%</strong></p></td><td style="vertical-align:top"><p><strong>Not recommended</strong></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Antineoplastics Agents</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Idelalisib</strong></p></td><td style="vertical-align:top"><p><strong>Although not studied</strong></p><p><strong>directly, idelalisib is likely to increase the</strong></p><p><strong>concentrations of itraconazole</strong></p></td><td style="vertical-align:top"><p><strong>Use with caution</strong></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Antivirals for Systemic Use</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Ombitasvir/Paritaprevir/Rit</strong><strong> </strong><strong>onavir (with or without Dasabuvir)</strong></p></td><td style="vertical-align:top"><p><strong>Although not studied directly, these drugs are expected to increase the concentrations of itraconazole</strong></p></td><td style="vertical-align:top"><p><strong>Contraindicated</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Efavirenz 600 mg</strong></p></td><td style="vertical-align:top"><p><strong>Itraconazole Cmax &darr; 37%, AUC &darr; 39%;</strong></p><p><strong>Hydroxyitraconazole Cmax &darr; 35%, AUC &darr; 37%</strong></p></td><td style="vertical-align:top"><p><strong>Not recommended</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Nevirapine PO 200 mg OD</strong></p></td><td style="vertical-align:top"><p><strong>Itraconazole Cmax &darr; 38%, AUC &darr; 62%</strong></p></td><td style="vertical-align:top"><p><strong>Not recommended</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Cobicistat, Darunavir (boosted),</strong></p><p><strong>Elvitegravir (ritonavir- boosted), Fosamprenavir (ritonavirboosted),</strong></p></td><td style="vertical-align:top"><p><strong>Although not studied</strong></p><p><strong>directly, these drugs are expected to increase the concentrations of itraconazole</strong></p></td><td style="vertical-align:top"><p><strong>Use with caution</strong></p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Ritonavir, Saquinavir (ritonavir-</strong></p><p><strong>boosted)</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Indinavir PO 800 mg TID</strong></p></td><td style="vertical-align:top"><p><strong>Itraconazole concentration &uarr;</strong></p></td><td style="vertical-align:top"><p><strong>Use with caution</strong></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Calcium Channel Blockers</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Diltiazem</strong></p></td><td style="vertical-align:top"><p><strong>Although not studied</strong></p><p><strong>directly, diltiazem is likely to increase the</strong></p><p><strong>concentration of itraconazole</strong></p></td><td style="vertical-align:top"><p><strong>Use with caution</strong></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Respiratory System: Other Respiratory System Products</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Lumacaftor/Ivacaftor PO 200/250</strong></p><p><strong>mg BID</strong></p></td><td style="vertical-align:top"><p><strong>Itraconazole concentration &darr;</strong></p></td><td style="vertical-align:top"><p><strong>Not recommended</strong></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Miscellaneous</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>St. John&#39;s Wort (Hypericum perforatum)</strong></p></td><td style="vertical-align:top"><p><strong>Although not studied</strong></p><p><strong>directly, St. John&#39;s </strong><strong>Wort islikely to</strong><strong> </strong><strong>decrease the</strong></p><p><strong>concentration of itraconazole</strong></p></td><td style="vertical-align:top"><p><strong>Not recommended</strong></p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong><u>Table 2: Examples of drugs that may have their plasma concentrations impacted by</u></strong><strong> </strong><strong><u>itraconazole, presented by drug class</u></strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Medicinal products (PO Single Dose unless otherwise stated) within class</strong></p></td><td style="vertical-align:top"><p><strong>Expected/Potential effect on drug levels</strong></p><p><strong>(&uarr; = increase; &harr; = no change; &darr; = decrease)</strong></p></td><td style="vertical-align:top"><p><strong>Clinical comment</strong></p><p><strong>(see above for additional</strong></p><p><strong>info and also sections 4.3 and 4.4)</strong></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Analgesics; Anaesthetics</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Ergot alkaloids (eg, dihydroergotamine,</strong></p><p><strong>ergometrine, ergotamine, methylergometrine)</strong></p></td><td style="vertical-align:top"><p><strong>Although not studied directly, itraconazole is likely to increase the concentrations of these drugs</strong></p></td><td style="vertical-align:top"><p><strong>Contraindicated</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Eletriptan, Fentanyl</strong></p></td><td style="vertical-align:top"><p><strong>Although not studied directly,</strong></p><p><strong>itraconazole is likely to increase the concentrations of these drugs</strong></p></td><td style="vertical-align:top"><p><strong>Not recommended</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Alfentanil, Buprenorphine (IV and sublingual),</strong></p><p><strong>Cannabinoids, Methadone, Sufentanil</strong></p></td><td style="vertical-align:top"><p><strong>Although not studied directly, itraconazole is likely to increase the concentrations of these drugs</strong></p></td><td style="vertical-align:top"><p><strong>Use with caution</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Oxycodone PO 10 mg</strong></p></td><td style="vertical-align:top"><p><strong>Oxycodone PO: Cmax &uarr; 45%, AUC &uarr; 2.4-fold</strong></p></td><td style="vertical-align:top"><p><strong>Use with caution</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Oxycodone IV 0.1 mg/kg</strong></p></td><td style="vertical-align:top"><p><strong>Oxycodone IV: AUC &uarr; 51%</strong></p></td><td style="vertical-align:top"><p><strong>Use with caution</strong></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Anti-bacterials for Systemic Use; Anti-mycobacterials; Antimycotics for Systemic Use</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Isavuconazole</strong></p></td><td style="vertical-align:top"><p><strong>Although not studied directly,</strong></p><p><strong>itraconazole is likely to increase the concentrations of isavuconazole</strong></p></td><td style="vertical-align:top"><p><strong>Contraindicated</strong></p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Bedaquiline</strong></p></td><td style="vertical-align:top"><p><strong>Although not studied directly, itraconazole is likely to increase</strong></p><p><strong>the concentrations of bedaquiline</strong></p></td><td style="vertical-align:top"><p><strong>Not recommended</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Rifabutin PO 300 mg OD</strong></p></td><td style="vertical-align:top"><p><strong>Rifabutin concentration &uarr; (extent unknown)</strong></p></td><td style="vertical-align:top"><p><strong>Not recommended</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Clarithromycin PO 500 mg BID</strong></p></td><td style="vertical-align:top"><p><strong>Clarithromycin concentration &uarr;</strong></p></td><td style="vertical-align:top"><p><strong>Use with caution</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Delamanid</strong></p></td><td style="vertical-align:top"><p><strong>Although not studied directly, itraconazole is likely to increase</strong></p><p><strong>the concentrations of delamanid</strong></p></td><td style="vertical-align:top"><p><strong>Use with caution</strong></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Antiepileptics</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Carbamazepine</strong></p></td><td style="vertical-align:top"><p><strong>Although not studied directly, itraconazole is likely to increase the concentrations of</strong></p><p><strong>carbamazepine</strong></p></td><td style="vertical-align:top"><p><strong>Not recommended</strong></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Anti-inflammatory and Antirheumatic Products</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Meloxicam 15 mg</strong></p></td><td style="vertical-align:top"><p><strong>Meloxicam Cmax &darr; 64%, AUC &darr; 37%</strong></p></td><td style="vertical-align:top"><p><strong>Use with caution</strong></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Anthelmintics; Antiprotozoals</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Halofantrine</strong></p></td><td style="vertical-align:top"><p><strong>Although not studied directly,</strong></p><p><strong>itraconazole is likely to increase the concentrations of halofantrine</strong></p></td><td style="vertical-align:top"><p><strong>Contraindicated</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Artemether-lumefantrine, Praziquantel</strong></p></td><td style="vertical-align:top"><p><strong>Although not studied directly, itraconazole is likely to increase</strong></p><p><strong>the concentrations of these drugs</strong></p></td><td style="vertical-align:top"><p><strong>Use with caution</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Quinine 300 mg</strong></p></td><td style="vertical-align:top"><p><strong>Quinine Cmax &harr;, AUC &uarr; 96%</strong></p></td><td style="vertical-align:top"><p><strong>Use with caution</strong></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Antihistamines for Systemic Use</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Astemizole, Mizolastine, Terfenadine</strong></p></td><td style="vertical-align:top"><p><strong>Although not studied directly, itraconazole is likely to increase the concentrations of these drugs</strong></p></td><td style="vertical-align:top"><p><strong>Contraindicated</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Ebastine 20 mg</strong></p></td><td style="vertical-align:top"><p><strong>Ebastine Cmax &uarr; 2.5-fold, AUC &uarr;</strong></p><p><strong>6.2-fold Carebastine Cmax &harr;, AUC &uarr; 3.1-fold</strong></p></td><td style="vertical-align:top"><p><strong>Not recommended</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Bilastine, Rupatadine</strong></p></td><td style="vertical-align:top"><p><strong>Although not studied directly, itraconazole is likely to increase</strong></p><p><strong>the concentrations of these drugs</strong></p></td><td style="vertical-align:top"><p><strong>Use with caution</strong></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Antineoplastic Agents</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Irinotecan</strong></p></td><td style="vertical-align:top"><p><strong>Although not studied directly, itraconazole is likely to increase</strong></p><p><strong>the concentrations of irinotecan and its active metabolite.</strong></p></td><td style="vertical-align:top"><p><strong>Contraindicated</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Venetoclax</strong></p></td><td style="vertical-align:top"><p><strong>Potential for an increased risk of tumor lysis syndrome</strong></p></td><td style="vertical-align:top"><p><strong>Contraindicated during the dose initiation and ramp-up phase in patients with CLL/SLL. Refer to the venetoclax prescribing information for dosing and</strong></p><p><strong>safety monitoring instructions</strong></p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Axitinib, Bosutinib, Cabazitaxel, Cabozantinib, Ceritinib, Crizotinib, Dabrafenib, Dasatinib, Docetaxel, Everolimus, Ibrutinib, Lapatinib, Nilotinib, Pazopanib, Regorafenib, Sunitinib, Temsirolimus, Trabectedin, Trastuzumab emtansine, Vinca alkaloids (eg,</strong></p><p><strong>vinflunine, vinorelbine)</strong></p></td><td style="vertical-align:top"><p><strong>Although not studied directly, itraconazole is likely to increase the concentrations of these drugs except for cabazitaxel and regorafenib. No statistically significant change in cabazitaxel exposure, but a high variability in the results was observed.</strong></p><p><strong>Regorafenib AUC is expected to decrease (by estimation of active moiety)</strong></p></td><td style="vertical-align:top"><p><strong>Not recommended</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Cobimetinib 10 mg</strong></p></td><td style="vertical-align:top"><p><strong>Cobimetinib Cmax &uarr; 3.2-fold, AUC</strong></p><p><strong>&uarr; 6.7-fold</strong></p></td><td style="vertical-align:top"><p><strong>Not recommended</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Olaparib 100 mg</strong></p></td><td style="vertical-align:top"><p><strong>Olaparib Cmax &uarr; 40%, AUC &uarr; 2.7- fold</strong></p></td><td style="vertical-align:top"><p><strong>Not recommended</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Alitretinoin (oral), Bortezomib, Brentuximab vedotin, Erlotinib, Idelalisib, Imatinib, Nintedanib,</strong></p><p><strong>Panobinostat, Ponatinib, Ruxolitinib, Sonidegib</strong></p></td><td style="vertical-align:top"><p><strong>Although not studied directly, itraconazole is likely to increase the concentrations of these drugs</strong></p></td><td style="vertical-align:top"><p><strong>Use with caution</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Busulfan 1 mg/kg Q6h</strong></p></td><td style="vertical-align:top"><p><strong>Busulfan Cmax &uarr;, AUC &uarr;</strong></p></td><td style="vertical-align:top"><p><strong>Use with caution</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Gefitinib 250 mg</strong></p></td><td style="vertical-align:top"><p><strong>Gefitinib 250 mg Cmax &uarr;, AUC &uarr; 78%</strong></p></td><td style="vertical-align:top"><p><strong>Use with caution</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Mobocertinib*</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Entrectinib*</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Pemigatinib*</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Immunosuppressants</strong></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Voclosporin</strong></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Antithrombotic Agents</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Dabigatran, Ticagrelor</strong></p></td><td style="vertical-align:top"><p><strong>Although not studied directly, itraconazole is likely to increase the concentrations of these drugs</strong></p></td><td style="vertical-align:top"><p><strong>Contraindicated</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Apixaban, Rivaroxaban, Vorapaxar</strong></p></td><td style="vertical-align:top"><p><strong>Although not studied directly, itraconazole is likely to increase</strong></p><p><strong>the concentrations of these drugs</strong></p></td><td style="vertical-align:top"><p><strong>Not recommended</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Cilostazol, Coumarins (eg, warfarin)</strong></p></td><td style="vertical-align:top"><p><strong>Although not studied directly, itraconazole is likely to increase the concentrations of these drugs</strong></p></td><td style="vertical-align:top"><p><strong>Use with caution</strong></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Antivirals for Systemic Use</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Ombitasvir/Paritaprevir/Rit</strong><strong> </strong><strong>onavir (with or without</strong></p><p><strong>Dasabuvir)</strong></p></td><td style="vertical-align:top"><p><strong>Itraconazole may increase paritaprevir concentrations</strong></p></td><td style="vertical-align:top"><p><strong>Contraindicated</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Elbasvir/Grazoprevir, Simeprevir, Tenofovir alafenamide fumarate (TAF), Tenofovir disoproxil</strong></p><p><strong>fumarate (TDF)</strong></p></td><td style="vertical-align:top"><p><strong>Although not studied directly, itraconazole is likely to increase the concentrations of these drugs</strong></p></td><td style="vertical-align:top"><p><strong>Not recommended</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Cobicistat, Elvitegravir (ritonavir-boosted),</strong></p><p><strong>lecaprevir/Pibrentasvir,</strong></p></td><td style="vertical-align:top"><p><strong>Although not studied directly, itraconazole is likely to increase</strong></p><p><strong>the concentrations of these drugs</strong></p></td><td style="vertical-align:top"><p><strong>Use with caution</strong></p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Maraviroc, Ritonavir, Saquinavi</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Indinavir PO 800 mg TID</strong></p></td><td style="vertical-align:top"><p><strong>Indinavir Cmax &harr;, AUC &uarr;</strong></p></td><td style="vertical-align:top"><p><strong>Use with caution</strong></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Cardiovascular System (Agents Acting on the Renin-Angiotensin System; Antihypertensives; Beta Blocking Agents; Calcium Channel Blockers; Cardiac Therapy; Diuretics)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Bepridil, Disopyramide, Dofetilide, Dronedarone, Eplerenone, Ivabradine, Lercanidipine, Nisoldipine, Ranolazine, Sildenafil</strong></p><p><strong>(pulmonary hypertension)</strong></p></td><td style="vertical-align:top"><p><strong>Although not studied directly, itraconazole is likely to increase the concentrations of these drugs.</strong></p></td><td style="vertical-align:top"><p><strong>Contraindicated</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Aliskiren 150 mg</strong></p></td><td style="vertical-align:top"><p><strong>Aliskiren Cmax &uarr; 5.8-fold, AUC &uarr; 6.5-fold</strong></p></td><td style="vertical-align:top"><p><strong>Contraindicated</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Quinidine 100 mg</strong></p></td><td style="vertical-align:top"><p><strong>Quinidine Cmax &uarr; 59%, AUC &uarr; 2.4-fold</strong></p></td><td style="vertical-align:top"><p><strong>Contraindicated</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Felodipine 5 mg</strong></p></td><td style="vertical-align:top"><p><strong>Felodipine Cmax &uarr; 7.8-fold, AUC &uarr; 6.3-fold</strong></p></td><td style="vertical-align:top"><p><strong>Not recommended</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Riociguat, Tadalafil (pulmonary hypertension)</strong></p></td><td style="vertical-align:top"><p><strong>Although not studied directly,</strong></p><p><strong>itraconazole is likely to increase the concentrations of these drugs</strong></p></td><td style="vertical-align:top"><p><strong>Not recommended</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Bosentan, Diltiazem, Guanfacine, Other Dihydropyridines (eg, amlodipine, isradipine,</strong></p><p><strong>nifedipine, nimodipine), Verapamil</strong></p></td><td style="vertical-align:top"><p><strong>Although not studied directly, itraconazole is likely to increase the concentrations of bosentan</strong></p></td><td style="vertical-align:top"><p><strong>Use with caution</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Digoxin 0.5 mg</strong></p></td><td style="vertical-align:top"><p><strong>Digoxin Cmax &uarr; 34%, AUC &uarr; 68%</strong></p></td><td style="vertical-align:top"><p><strong>Use with caution</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Nadolol 30 mg</strong></p></td><td style="vertical-align:top"><p><strong>Nadolol Cmax &uarr; 4.7-fold, AUC &uarr; 2.2-fold</strong></p></td><td style="vertical-align:top"><p><strong>Use with caution</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Finerenone</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Corticosteroids for Systemic Use; Drugs for Obstructive Airway Diseases</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Ciclesonide, Salmeterol</strong></p></td><td style="vertical-align:top"><p><strong>Although not studied directly, itraconazole is likely to increase the concentrations of salmeterol</strong></p><p><strong>and the active metabolite of ciclesonide</strong></p></td><td style="vertical-align:top"><p><strong>Not recommended</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Budesonide INH 1 mg SD</strong></p></td><td style="vertical-align:top"><p><strong>Budesonide INH Cmax &uarr; 65%, AUC &uarr; 4.2-fold; Budesonide (other</strong></p><p><strong>formulations) concentration &uarr;</strong></p></td><td style="vertical-align:top"><p><strong>Use with caution</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Dexamethasone IV 5 mg Dexamethasone PO 4.5 mg</strong></p></td><td style="vertical-align:top"><p><strong>Dexamethasone IV: Cmax &harr;, AUC &uarr; 3.3-fold Dexamethasone PO: Cmax &uarr; 69%, AUC &uarr; 3.7-fold</strong></p></td><td style="vertical-align:top"><p><strong>Use with caution</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Fluticasone INH 1 mg BID</strong></p></td><td style="vertical-align:top"><p><strong>Fluticasone INH concentration &uarr;</strong></p></td><td style="vertical-align:top"><p><strong>Use with caution</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Methylprednisolone 16 mg</strong></p></td><td style="vertical-align:top"><p><strong>Methylprednisolone PO Cmax &uarr; 92%, AUC &uarr; 3.9-fold</strong></p><p><strong>Methylprednisolone IV AUC &uarr; 2.6- fold</strong></p></td><td style="vertical-align:top"><p><strong>Use with caution</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Fluticasone nasal</strong></p></td><td style="vertical-align:top"><p><strong>Although not studied directly, itraconazole is likely to increase the concentrations of</strong></p><p><strong>nasallyadministered fluticasone</strong></p></td><td style="vertical-align:top"><p><strong>Use with caution</strong></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Drugs Used in Diabetes</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Repaglinide 0.25 mg</strong></p></td><td style="vertical-align:top"><p><strong>Repaglinide Cmax &uarr; 47%, AUC &uarr;</strong></p></td><td style="vertical-align:top"><p><strong>Use with caution</strong></p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>41%</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Saxagliptin</strong></p></td><td style="vertical-align:top"><p><strong>Although not studied directly,</strong></p><p><strong>itraconazole is likely to increase the concentrations of saxagliptin</strong></p></td><td style="vertical-align:top"><p><strong>Use with caution</strong></p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Gastrointestinal Drugs, including Antidiarrheals, Intestinal Anti-inflammatory/Antiinfective Agents; Antiemetics and Antinauseants; Drugs for Constipation; Drugs for Functional</strong></p><p><strong>Gastrointestinal Disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Cisapride, Naloxegol</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Although not studied directly, itraconazole is likely to increase the concentrations of these drugs</strong></p></td><td style="vertical-align:top"><p><strong>Contraindicated</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Domperidone 20 mg</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Domperidone Cmax &uarr; 2.7- fold, AUC &uarr; 3.2-fold</strong></p></td><td style="vertical-align:top"><p><strong>Contraindicated</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Aprepitant, Loperamide, Netupitant</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Although not studied directly,</strong></p><p><strong>itraconazole is likely to increase the concentrations of aprepitant</strong></p></td><td style="vertical-align:top"><p><strong>Use with caution</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Sirolimus (rapamycin)</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Although not studied directly, itraconazole is likely to increase the</strong></p><p><strong>concentrations of sirolimus</strong></p></td><td style="vertical-align:top"><p><strong>Not recommended</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Cyclosporine, Tacrolimus</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Although not studied directly, itraconazole is likely to increase the concentrations of cyclosporine</strong></p></td><td style="vertical-align:top"><p><strong>Use with caution</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Tacrolimus IV 0.03 mg/kg OD</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Tacrolimus IV concentration &uarr;</strong></p></td><td style="vertical-align:top"><p><strong>Use with caution</strong></p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Lipid Modifying Agents</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Lomitapide</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Although not studied directly, itraconazole is likely to increase the concentrations of lomitapide</strong></p></td><td style="vertical-align:top"><p><strong>Contraindicated</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Lovastatin 40 mg</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Lovastatin Cmax &uarr; 14.5-&gt;20- fold, AUC &uarr; &gt;14.8 - &gt;20- fold Lovastatin</strong></p><p><strong>acid Cmax &uarr; 11.5- 13-fold, AUC &uarr; 15.4-20- fold</strong></p></td><td style="vertical-align:top"><p><strong>Contraindicated</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Simvastatin 40 mg</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Simvastatin acid Cmax &uarr; 17- fold, AUC &uarr; 19-fold</strong></p></td><td style="vertical-align:top"><p><strong>Contraindicated</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Atorvastatin</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Atorvastatin acid: Cmax &harr; to &uarr;2.5- fold, AUC &uarr; 40% to 3- fold</strong></p></td><td style="vertical-align:top"><p><strong>Not recommended</strong></p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Psychoanaleptics; Psycholeptics (eg, antipsychotics, anxiolytics, and hypnotics)</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Lurasidone, Pimozide, Quetiapine, Sertindole</strong></p></td><td style="vertical-align:top"><p><strong>Although not studied directly, itraconazole is likely to increase the concentrations of these drugs</strong></p></td><td style="vertical-align:top"><p><strong>Contraindicated</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Midazolam (oral) 7.5 mg</strong></p></td><td style="vertical-align:top"><p><strong>Midazolam (oral) Cmax &uarr; 2.5 to 3.4-fold, AUC &uarr; 6.6 to 10.8-fold</strong></p></td><td style="vertical-align:top"><p><strong>Contraindicated</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Triazolam 0.25 mg</strong></p></td><td style="vertical-align:top"><p><strong>Triazolam Cmax &uarr;, AUC &uarr;</strong></p></td><td style="vertical-align:top"><p><strong>Contraindicated</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Alprazolam 0.8 mg</strong></p></td><td style="vertical-align:top"><p><strong>Alprazolam Cmax &harr;, AUC &uarr; 2.8- fold</strong></p></td><td style="vertical-align:top"><p><strong>Use with caution</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Aripiprazole 3 mg</strong></p></td><td style="vertical-align:top"><p><strong>Aripiprazole Cmax &uarr; 19%, AUC &uarr; 48%</strong></p></td><td style="vertical-align:top"><p><strong>Use with caution</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Brotizolam 0.5 mg</strong></p></td><td style="vertical-align:top"><p><strong>Brotizolam Cmax &harr;, AUC &uarr; 2.6- fold</strong></p></td><td style="vertical-align:top"><p><strong>Use with caution</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Buspirone 10 mg</strong></p></td><td style="vertical-align:top"><p><strong>Buspirone Cmax &uarr; 13.4-fold, AUC</strong></p><p><strong>&uarr; 19.2-fold</strong></p></td><td style="vertical-align:top"><p><strong>Use with caution</strong></p></td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="2" style="vertical-align:top"><p><strong>Midazolam (iv) 7.5 mg</strong></p></td><td style="vertical-align:top"><p><strong>Midazolam (iv) 7.5 mg: concentration &uarr;; Although not studied directly, itraconazole is likely to increase the concentrations of midazolam following oromucosal</strong></p><p><strong>administration</strong></p></td><td style="vertical-align:top"><p><strong>Use with caution</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Risperidone 2-8 mg/day</strong></p></td><td style="vertical-align:top"><p><strong>Risperidone and active metabolite concentration &uarr;</strong></p></td><td style="vertical-align:top"><p><strong>Use with caution</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Zopiclone 7.5 mg</strong></p></td><td style="vertical-align:top"><p><strong>Zopiclone Cmax &uarr; 30%, AUC &uarr; 70%</strong></p></td><td style="vertical-align:top"><p><strong>Use with caution</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Cariprazine, Galantamine, Haloperidol, Reboxetine, Venlafaxine</strong></p></td><td style="vertical-align:top"><p><strong>Although not studied directly, itraconazole is likely to increase the concentrations of these drugs</strong></p></td><td style="vertical-align:top"><p><strong>Use with caution</strong></p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Respiratory System: Other Respiratory System Products</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Lumacaftor/Ivacaftor PO 200/250 mg BID</strong></p></td><td style="vertical-align:top"><p><strong>Ivacaftor Cmax &uarr; 3.6-fold, AUC &uarr; 4.3-fold Lumacaftor Cmax &harr;, AUC &harr;</strong></p></td><td style="vertical-align:top"><p><strong>Not recommended</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Ivacaftor</strong></p></td><td style="vertical-align:top"><p><strong>Although not studied directly, itraconazole is likely to increase the concentrations of ivacaftor</strong></p></td><td style="vertical-align:top"><p><strong>Use with caution</strong></p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Sex Hormones and Modulators of the Genital System; Other Gynaecologicals</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Cabergoline, Dienogest, Ulipristal</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Although not studied directly, itraconazole is likely to increase the concentrations of these drugs</strong></p></td><td style="vertical-align:top"><p><strong>Use with caution</strong></p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Urologicals</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Avanafil, Dapoxetine, Darifenacin</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Although not studied directly, itraconazole is likely to increase the concentrations of these drugs</strong></p></td><td style="vertical-align:top"><p><strong>Contraindicated</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Fesoterodine</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Although not studied directly, itraconazole is likely to increase the concentrations of the active metabolites, 5- hydroxymethyl tolterodine</strong></p></td><td style="vertical-align:top"><p><strong>Moderate or severe renal or hepatic impairment: Contraindicated Mild renal or hepatic impairment: Concomitant use should be avoided Normal renal or hepatic impairment: Use with caution with a maximum fesoterodine dose</strong></p><p><strong>of 4 mg</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Solifenacin</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Although not studied directly, itraconazole is likely to increase the concentrations of solifenacin</strong></p></td><td style="vertical-align:top"><p><strong>Severe renal impairment: Contraindicated Moderate or severe hepatic impairment: Contraindicated Use with caution in all other patients with a maximum</strong></p><p><strong>solifenacin dose of 5 mg</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Vardenafil</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Although not studied directly, itraconazole is likely to increase the concentrations of vardenafil</strong></p></td><td style="vertical-align:top"><p><strong>Contraindicated in patients older than 75 years; otherwise not recommended</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Alfuzosin, Silodosin, Tadalafil (erectile dysfunction and benign</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Although not studied directly, itraconazole is likely to increase the concentrations of these drugs</strong></p></td><td style="vertical-align:top"><p><strong>Not recommended</strong></p></td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>prostatic hyperplasia), Tamsulosin, Tolterodine</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Dutasteride, Imidafenacin,</strong></p><p><strong>Sildenafil (erectile dysfunction)</strong></p></td><td style="vertical-align:top"><p><strong>Although not studied directly,</strong></p><p><strong>itraconazole is likely to increase the concentrations of these drugs</strong></p></td><td style="vertical-align:top"><p><strong>Use with caution</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Oxybutynin 5 mg</strong></p></td><td style="vertical-align:top"><p><strong>Oxybutynin Cmax &uarr; 2-fold, AUC &uarr; 2-fold N-desethyloxybutynin Cmax</strong></p><p><strong>&harr;, AUC &harr;</strong></p><p><strong>Following transdermal administration: Although not studied directly, itraconazole is likely to increase the concentrations of oxybutynin following</strong></p><p><strong>transdermal administration</strong></p></td><td style="vertical-align:top"><p><strong>Use with caution</strong></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Miscellaneous Drugs and Other Substances</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Colchicine</strong></p></td><td style="vertical-align:top"><p><strong>Although not studied directly, itraconazole is likely to increase the concentrations of colchicine</strong></p></td><td style="vertical-align:top"><p><strong>Contraindicated in patients with renal or hepatic impairment. Not</strong></p><p><strong>recommended in other patients.</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Eliglustat</strong></p></td><td style="vertical-align:top"><p><strong>Although not directly studied, itraconazole is expected to increase the concentrations of eliglustat</strong></p></td><td style="vertical-align:top"><p><strong>Contraindicated in CYP2D6 poor metabolisers (PM). Contraindicated in CYP2D6 intermediate metabolisers (IMs) or extensive metabolisers (EMs) taking a strong or moderate CYP2D6 inhibitor. Use with caution in CYP2D6 IMs and EMs. In CYP2D6 EMs with mild hepatic impairment, an eliglustat dose of 84 mg/day should be considered</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Cinacalcet</strong></p></td><td style="vertical-align:top"><p><strong>Although not studied directly, itraconazole is likely to increase the concentrations of cinacalcet</strong></p></td><td style="vertical-align:top"><p><strong>Use with caution</strong></p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p>* Based on clinical drug interaction information with itraconazole.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em><u>Pregnancy</u></em></p><p>ITRAZOL&reg; must not be used during pregnancy except for life-threatening cases where the potential benefit to the mother outweighs the potential harm to the foetus (See section 4.3).</p><p>In animal studies itraconazole has shown reproduction toxicity (see section 5.3). There is limited information on the use of ITRAZOL&reg; during pregnancy. During post-</p><p>&nbsp;</p><p>marketing experience, cases of congenital abnormalities have been reported. These cases&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; included&nbsp;&nbsp; skeletal,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; genitourinary&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tract,&nbsp; &nbsp;cardiovascular&nbsp; &nbsp;and&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ophthalmic malformations as well as chromosomal and multiple malformations. A causal relationship with ITRAZOL&reg; has not been established.</p><p>Epidemiological data on exposure to ITRAZOL&reg; during the first trimester of pregnancy &ndash; mostly in patients receiving short-term treatment for vulvovaginal candidosis &ndash; did not show an increased risk for malformations as compared to control subjects not exposed to any known teratogens.</p><p><em><u>Women of childbearing potential</u></em></p><p>Women of childbearing potential taking ITRAZOL&reg; capsules should use contraceptive precautions. Effective contraception should be continued until the menstrual period following the end of ITRAZOL&reg; therapy.</p><p><em><u>Lactation</u></em></p><p>A very small amount of itraconazole is excreted in human milk. The expected benefits of ITRAZOL&reg; therapy should be weighed against the risks of breast feeding. In case of doubt, the patient should not breast feed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies on the effects on the ability to drive and use machines have been performed. When driving vehicles and operating machinery the possibility of adverse reactions such as dizziness, visual disturbances and hearing loss (see Section 4.8), which may occur in some instances, must be taken into account.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong><u>Tabulated list of AE:</u></strong></p><p>Undesirable effects listed below have been reported in clinical trials with ITRAZOL&reg; capsules and/or from spontaneous reports from post-marketing experience for all ITRAZOL&reg; formulations.</p><p>In double-blind, controlled clinical trials involving 2104 itraconazole-treated patients in the treatment of dermatomycoses or onychomycosis, the most frequently reported adverse experiences in clinical trials were of gastrointestinal, dermatological, and hepatic origin.</p><p>The table below presents adverse drug reactions by System Organ Class. Within each System Organ Class, the adverse drug reactions are presented by incidence category, using the following convention:</p><p><!--[if gte vml 1]><v:shapetype
 id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
 path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="image1.png" o:spid="_x0000_s1031" type="#_x0000_t75"
 style='position:absolute;left:0;text-align:left;margin-left:169.55pt;
 margin-top:4.4pt;width:4.35pt;height:5.75pt;z-index:-17185280;visibility:visible;
 mso-wrap-style:square;mso-wrap-distance-left:0;mso-wrap-distance-top:0;
 mso-wrap-distance-right:0;mso-wrap-distance-bottom:0;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:page;
 mso-position-vertical:absolute;mso-position-vertical-relative:text'>
 <v:imagedata src="file:///C:/Users/AMR~1.MAK/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png"
  o:title=""/>
 <w:wrap anchorx="page"/>
</v:shape><![endif]--><img width="6" height="8" src="file:///C:/Users/AMR~1.MAK/AppData/Local/Temp/msohtmlclip1/01/clip_image002.gif" /><!--[if gte vml 1]><v:shape id="_x0000_s1030"
 type="#_x0000_t75" style='position:absolute;left:0;text-align:left;
 margin-left:267.85pt;margin-top:4.4pt;width:4.3pt;height:5.75pt;z-index:-17184768;
 visibility:visible;mso-wrap-style:square;mso-wrap-distance-left:0;
 mso-wrap-distance-top:0;mso-wrap-distance-right:0;mso-wrap-distance-bottom:0;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:page;
 mso-position-vertical:absolute;mso-position-vertical-relative:text'>
 <v:imagedata src="file:///C:/Users/AMR~1.MAK/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png"
  o:title=""/>
 <w:wrap anchorx="page"/>
</v:shape><![endif]--><img width="6" height="8" src="file:///C:/Users/AMR~1.MAK/AppData/Local/Temp/msohtmlclip1/01/clip_image002.gif" /><!--[if gte vml 1]><v:shape id="_x0000_s1029"
 type="#_x0000_t75" style='position:absolute;left:0;text-align:left;
 margin-left:434.15pt;margin-top:4.4pt;width:4.35pt;height:5.75pt;z-index:-17184256;
 visibility:visible;mso-wrap-style:square;mso-wrap-distance-left:0;
 mso-wrap-distance-top:0;mso-wrap-distance-right:0;mso-wrap-distance-bottom:0;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:page;
 mso-position-vertical:absolute;mso-position-vertical-relative:text'>
 <v:imagedata src="file:///C:/Users/AMR~1.MAK/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png"
  o:title=""/>
 <w:wrap anchorx="page"/>
</v:shape><![endif]--><img width="6" height="8" src="file:///C:/Users/AMR~1.MAK/AppData/Local/Temp/msohtmlclip1/01/clip_image002.gif" /><!--[if gte vml 1]><v:shape id="_x0000_s1028"
 type="#_x0000_t75" style='position:absolute;left:0;text-align:left;
 margin-left:162.6pt;margin-top:19pt;width:4.3pt;height:5.8pt;z-index:-17183744;
 visibility:visible;mso-wrap-style:square;mso-wrap-distance-left:0;
 mso-wrap-distance-top:0;mso-wrap-distance-right:0;mso-wrap-distance-bottom:0;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:page;
 mso-position-vertical:absolute;mso-position-vertical-relative:text'>
 <v:imagedata src="file:///C:/Users/AMR~1.MAK/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png"
  o:title=""/>
 <w:wrap anchorx="page"/>
</v:shape><![endif]--><img width="6" height="8" src="file:///C:/Users/AMR~1.MAK/AppData/Local/Temp/msohtmlclip1/01/clip_image002.gif" />Very common ( 1/10); Common ( 1/100 to &lt; 1/10); Uncommon ( 1/1,000 to &lt; 1/100); Rare (&nbsp;&nbsp;&nbsp; &nbsp;1/10,000 to &lt; 1/1,000); Very rare (&lt; 1/10,000), Not known (cannot be estimated from the available data).</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2" style="vertical-align:top"><p>MedDRA System Organ Class</p></td><td colspan="6" style="vertical-align:top"><p>Adverse reactions / Frequency</p></td></tr><tr><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Not known</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Blood and lymphatic system disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Leukopenia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Neutropenia, Thrombocytopenia</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Immune system disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hypersensitivity*</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Anaphylactic Reaction, Anaphylactoid Reaction, Angioneurotic Oedema, Serum Sickness</p></td></tr><tr><td style="vertical-align:top"><p>Metabolism and nutrition disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hypokalemia, Hypertriglyceridem ia</p></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Headache, Dizziness,</p></td><td style="vertical-align:top"><p>Hypoaesthesia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Peripheral Neuropathy*</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Paraesthesia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Eye disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Visual Disturbance</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Vision Blurred and Diplopia</p></td></tr><tr><td style="vertical-align:top"><p>Ear and labyrinth disorder</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Tinnitus</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Transient or permanent Hearing Loss*</p></td></tr><tr><td style="vertical-align:top"><p>Cardiac disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Congestive Heart Failure*</p></td></tr><tr><td style="vertical-align:top"><p>Respiratory,tho racic and</p><p>mediastinal disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Dyspnoea</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Pulmonary Oedema</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Abdomin al Pain, Nausea</p></td><td style="vertical-align:top"><p>Vomiting, Diarrhoea, Constipation, Dyspepsia, Dysgeusia, Flatulence</p></td><td style="vertical-align:top"><p>Pancreatitis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Hepato-biliary disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hyperbilirubinae mia, Alanine Aminotransferase Increased, Aspartate Aminotransferase Increased</p></td><td style="vertical-align:top"><p>Hepatic Enzyme Increased</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Fatal Acute Hepatic Failure*, Hepatitis, Hepatotoxicity*</p></td></tr><tr><td style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rash</p></td><td style="vertical-align:top"><p>Urticaria, Alopecia, Pruritus</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Toxic Epidermal Necrolysis, Stevens-Johnson Syndrome, Acute generalised exanthematous pustulosis , Erythema Multiforme, Exfoliative Dermatitis, Leukocytoclastic Vasculitis, Photosensitivity</p></td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal</p><p>and connective</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Myalgia, Arthralgia</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>tissue disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>Renal and urinary disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Pollakiuria</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Urinary Incontinence</p></td></tr><tr><td style="vertical-align:top"><p>Reproductive system and breast disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Menstrual Disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Erectile Dysfunction</p></td></tr><tr><td style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Oedema</p></td><td style="vertical-align:top"><p>Pyrexia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p><em><u>*see</u></em><em><u> </u></em><em><u>section 4.4</u></em></p><p><em>&nbsp;</em></p><p><strong>b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong><u>Other special population:</u></strong></p><p><u>Use in Children (below 12 years): </u></p><p>Clinical data on the use of ITRAZOL&reg; capsules in paediatric patients are limited. ITRAZOL&reg; capsules should not be used in children unless the potential benefit outweighs the potential risks. (See Section 4.4 )</p><p><u>Use in Elderly </u><u>:</u></p><p>As for use in children</p><p><u>Use in patients with renal impairment</u><u>:</u></p><p>Limited data are available on the use of oral itraconazole in patients with renal impairment. Caution should be exercised when this drug is administered in this patient population .</p><p><u>Use in patients with hepatic impairment</u><u>:</u></p><p>Limited data are available on the use of oral itraconazole in patients with hepatic impairment. Caution should be exercised when this drug is administered in this patient population. (See Section 5.2).</p><p>&nbsp;</p><p>To report any side effect (s):</p><p><strong>Saudi Arabia:</strong></p><p><!--[if mso & !supportInlineShapes & supportFields]><span
style='font-size:10.0pt;mso-bidi-font-size:12.0pt'><span style='mso-element:
field-begin;mso-field-lock:yes'></span><span style='mso-spacerun:yes'> </span>SHAPE
<span style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:
field-separator'></span></span><![endif]--><!--[if gte vml 1]><v:shapetype id="_x0000_t202"
 coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
 <v:stroke joinstyle="miter"/>
 <v:path gradientshapeok="t" o:connecttype="rect"/>
</v:shapetype><v:shape id="_x0000_s1027" type="#_x0000_t202" style='width:390.2pt;
 height:59.8pt;mso-left-percent:-10001;mso-top-percent:-10001;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:char;
 mso-position-vertical:absolute;mso-position-vertical-relative:line;
 mso-left-percent:-10001;mso-top-percent:-10001' filled="f" strokeweight=".48pt">
 <v:textbox inset="0,0,0,0">
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoBodyText style='margin-top:.1pt;margin-right:0in;margin-bottom:
    0in;margin-left:5.15pt;margin-bottom:.0001pt'>-The<span style='letter-spacing:
    -.3pt'> </span>national<span style='letter-spacing:-.25pt'> </span>pharmacovigilance<span
    style='letter-spacing:-.1pt'> </span>center<span style='letter-spacing:
    -.2pt'> </span>(NPC):<o:p></o:p></p>
    <p class=MsoBodyText style='margin-top:.25pt;margin-right:0in;margin-bottom:
    0in;margin-left:5.15pt;margin-bottom:.0001pt'>-SFDA call<span
    style='letter-spacing:-.15pt'> </span>center:<span style='letter-spacing:
    -.15pt'> </span>19999<o:p></o:p></p>
    <p class=MsoBodyText style='margin-top:.1pt;margin-right:0in;margin-bottom:
    0in;margin-left:5.15pt;margin-bottom:.0001pt'>-E-mail:<span
    style='letter-spacing:-.3pt'> </span><a href="mailto:npc.drug@sfda.gov.sa"><span
    style='color:#006FC0;text-decoration:none;text-underline:none'>npc.drug@sfda.gov.sa</span></a><o:p></o:p></p>
    <p class=MsoBodyText style='margin-top:.1pt;margin-right:0in;margin-bottom:
    0in;margin-left:5.15pt;margin-bottom:.0001pt'>-Website:<span
    style='letter-spacing:-.4pt'> </span><a href="http://ade.sfda.gov.sa/"><span
    style='color:windowtext;text-decoration:none;text-underline:none'>http://ade.sfda.gov.sa</span></a><o:p></o:p></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
 <w:wrap type="none"/>
 <w:anchorlock/>
</v:shape><![endif]--><img width="526" height="86" alt="Text Box: -The national pharmacovigilance center (NPC):
-SFDA call center: 19999
-E-mail: npc.drug@sfda.gov.sa
-Website: http://ade.sfda.gov.sa
" src="file:///C:/Users/AMR~1.MAK/AppData/Local/Temp/msohtmlclip1/01/clip_image003.gif" /><!--[if mso & !supportInlineShapes & supportFields]><span
style='font-size:10.0pt;mso-bidi-font-size:12.0pt'><v:shape id="_x0000_i1025"
 type="#_x0000_t75" style='width:390.2pt;height:59.8pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span></span><![endif]--></p><p><strong>&nbsp;</strong></p><p><strong>Other GCC states and other countries:</strong></p><p><!--[if mso & !supportInlineShapes & supportFields]><span
style='font-size:10.0pt;mso-bidi-font-size:12.0pt'><span style='mso-element:
field-begin;mso-field-lock:yes'></span><span style='mso-spacerun:yes'> </span>SHAPE
<span style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:
field-separator'></span></span><![endif]--><!--[if gte vml 1]><v:shape id="_x0000_s1026"
 type="#_x0000_t202" style='width:390.2pt;height:15.4pt;mso-left-percent:-10001;
 mso-top-percent:-10001;mso-position-horizontal:absolute;
 mso-position-horizontal-relative:char;mso-position-vertical:absolute;
 mso-position-vertical-relative:line;mso-left-percent:-10001;mso-top-percent:-10001'
 filled="f" strokeweight=".48pt">
 <v:textbox inset="0,0,0,0">
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoBodyText style='margin-top:.2pt;margin-right:0in;margin-bottom:
    0in;margin-left:5.15pt;margin-bottom:.0001pt'>-Please<span
    style='letter-spacing:-.25pt'> </span>contact<span style='letter-spacing:
    -.25pt'> </span>the<span style='letter-spacing:-.25pt'> </span>relevant<span
    style='letter-spacing:-.1pt'> </span>competent<span style='letter-spacing:
    -.1pt'> </span>authority<o:p></o:p></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
 <w:wrap type="none"/>
 <w:anchorlock/>
</v:shape><![endif]--><img width="526" height="26" alt="Text Box: -Please contact the relevant competent authority" src="file:///C:/Users/AMR~1.MAK/AppData/Local/Temp/msohtmlclip1/01/clip_image004.gif" /><!--[if mso & !supportInlineShapes & supportFields]><span
style='font-size:10.0pt;mso-bidi-font-size:12.0pt'><v:shape id="_x0000_i1026"
 type="#_x0000_t75" style='width:390.2pt;height:15.4pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span></span><![endif]--></p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No data are available.</p><p>In the event of an overdose, supportive measures should be employed. Within the first hour after ingestion gastric lavage may be performed. Activated charcoal may</p><p>be&nbsp;&nbsp;&nbsp; given&nbsp;&nbsp;&nbsp; if&nbsp;&nbsp;&nbsp; considered&nbsp;&nbsp;&nbsp; appropriate.&nbsp;&nbsp;&nbsp; Itraconazole&nbsp;&nbsp;&nbsp; cannot&nbsp;&nbsp;&nbsp; be&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; removed&nbsp;&nbsp;&nbsp; by haemodialysis.</p><p><!--[if gte vml 1]><v:shapetype id="_x0000_t202" coordsize="21600,21600"
 o:spt="202" path="m,l,21600r21600,l21600,xe">
 <v:stroke joinstyle="miter"/>
 <v:path gradientshapeok="t" o:connecttype="rect"/>
</v:shapetype><v:shape id="_x0000_s1026" type="#_x0000_t202" style='position:absolute;
 left:0;text-align:left;margin-left:108pt;margin-top:14.5pt;width:398.85pt;
 height:14.65pt;z-index:15735808;mso-position-horizontal-relative:page'
 fillcolor="#d9d9d9" stroked="f">
 <v:textbox inset="0,0,0,0"/>
 <w:wrap anchorx="page"/>
</v:shape><![endif]--></p><p>No specific antidote is available.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic classification</p><p>Antimycotic for systemic use, triazole derivatives ATC code: J02A C02</p><p>Itraconazole, a triazole derivative, has a broad spectrum of activity.</p><p><em>In vitro </em>studies have demonstrated that itraconazole impairs the synthesis of ergosterol in fungal cells. Ergosterol is a vital cell membrane component in fungi. Impairment of its synthesis ultimately results in an antifungal effect.</p><p>For itraconazole, breakpoints have only been established for <em>Candida </em>spp. from superficial mycotic infections (CLSI M27-A2, breakpoints have not been established for EUCAST methodology). The CLSI breakpoints are as follows: susceptible &lt;0.125; susceptible, dose-dependent 0.25-0.5 and resistant &gt;1 &micro;g/mL. Interpretive breakpoints have not been established for the filamentous fungi.</p><p><!--[if gte vml 1]><v:shapetype
 id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
 path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="image2.png" o:spid="_x0000_s1027" type="#_x0000_t75"
 style='position:absolute;left:0;text-align:left;margin-left:361.1pt;
 margin-top:18.95pt;width:4.3pt;height:5.75pt;z-index:-17182208;visibility:visible;
 mso-wrap-style:square;mso-wrap-distance-left:0;mso-wrap-distance-top:0;
 mso-wrap-distance-right:0;mso-wrap-distance-bottom:0;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:page;
 mso-position-vertical:absolute;mso-position-vertical-relative:text'>
 <v:imagedata src="file:///C:/Users/AMR~1.MAK/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png"
  o:title=""/>
 <w:wrap anchorx="page"/>
</v:shape><![endif]--><img width="6" height="8" src="file:///C:/Users/AMR~1.MAK/AppData/Local/Temp/msohtmlclip1/01/clip_image002.gif" />In vitro studies demonstrate that itraconazole inhibits the growth of a broad range of fungi pathogenic for humans at concentrations usually&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1 &mu;g/ml. These include: dermatophytes (<em>Trichophyton spp., Microsporum spp., Epidermophyton floccosum); yeasts (Candida spp., </em>including <em>C. albicans, Cryptococcus neoformans, Malassezia spp., Trichosporon spp., Geotrichum spp.); Aspergillus spp.; Histoplasma spp.; Paracoccidioides brasiliensis; Sporothrix schenckii; Fonsecaea spp.; Cladosporium spp.; Blastomyces dermatitidis; Coccidioides immitis; Pseudallescheria boydii; Penicillium marneffei; </em>and various other yeasts and fungi.</p><p><em>Candida krusei, Candida glabrata </em>and <em>Candida tropicalis </em>are generally the least susceptible <em>Candida </em>species, with some isolates showing unequivocal resistance to itraconazole <em>in vitro</em>.</p><p>The principal fungus types that are not inhibited by itraconazole are <em>Zygomycetes </em>(e.g. <em>Rhizopus spp., Rhizomucor spp., Mucor spp. and Absidia spp.</em>), <em>Fusarium spp., Scedosporium spp. </em>and <em>Scopulariopsis spp.</em></p><p><!--[if gte vml 1]><v:shapetype id="_x0000_t202" coordsize="21600,21600" o:spt="202"
 path="m,l,21600r21600,l21600,xe">
 <v:stroke joinstyle="miter"/>
 <v:path gradientshapeok="t" o:connecttype="rect"/>
</v:shapetype><v:shape id="_x0000_s1026" type="#_x0000_t202" style='position:absolute;
 margin-left:108.25pt;margin-top:117.3pt;width:398.6pt;height:14.65pt;
 z-index:15734784;mso-position-horizontal-relative:page' fillcolor="#d9d9d9"
 stroked="f">
 <v:textbox inset="0,0,0,0"/>
 <w:wrap anchorx="page"/>
</v:shape><![endif]--></p><p>Azole resistance appears to develop slowly and is often the result of several genetic mutations. Mechanisms that have been described are overexpression of ERG11, which encodes the target enzyme 14&alpha;-demethylase, point mutations in ERG11 that lead to decreased target affinity and/or transporter overexpression resulting in increased efflux. Cross-resistance between members of the azole class has been observed within <em>Candida </em>spp., although resistance to one member of the class does not necessarily confer resistance to other azoles. Itraconazole-resistant strains of <em>Aspergillus fumigatus </em>have been reported.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>General pharmacokinetic characteristics:</em></p><p>&nbsp;</p><p>The pharmacokinetics of itraconazole has been investigated in healthy subjects, special populations and patients after single and multiple dosing. In general, itraconazole is well absorbed. Peak plasma concentrations are reached within 2 to 5 hours following administration of the oral solution. Itraconazole undergoes extensive hepatic metabolism to give numerous metabolites. The main metabolite is hydroxy- itraconazole, with plasma concentrations about twice those of the unchanged drug. The terminal half-life of itraconazole is about 40 hours after repeated dosing. The pharmacokinetics of itraconazole is characterised by non-linearity and, consequently, shows accumulation in plasma after multiple dose administration. Steady-state concentrations are reached within 15 days, with Cmax values of about 2 &mu;g/ml after oral administration of 200 mg once daily. Itraconazole clearance decreases at higher doses due to a saturable mechanism of its hepatic metabolism. Itraconazole is excreted as inactive metabolites in urine (~35%) and in faeces (~54%). <em>Absorption:</em></p><p>Itraconazole is rapidly absorbed after administration of the oral solution. Peak plasma concentrations of the unchanged drug are reached within 2 to 5 hours following an oral dose. The observed absolute bioavailability of itraconazole under fed conditions is about 55% Oral bioavailability is maximal when the capsules are taken immediately after a full meal.</p><p><em>Distribution:</em></p><p>Most of the itraconazole in plasma is bound to protein (99.8%) with albumin being the main binding component (99.6% for the hydroxy-metabolite). It has also a marked affinity for lipids. Only 0.2% of the itraconazole in plasma is present as free drug. Itraconazole is distributed in a large apparent volume in the body (&gt; 700 L), suggesting its extensive distribution into tissues:</p><p>Concentrations in lung, kidney, liver, bone, stomach, spleen and muscle were found to be two to three times higher than corresponding concentrations in plasma. Brain to plasma ratios were about 1.</p><p>The uptake into keratinous tissues, skin in particular, is up to four times higher than in plasma.</p><p><em>Metabolism:</em></p><p>Itraconazole is extensively metabolised by the liver into a large number of metabolites. The main metabolite is hydroxy-itraconazole which has in vitro antifungal activity comparable to itraconazole. Plasma concentrations of the hydroxy-metabolite are about twice those of itraconazole.</p><p>As shown in <em>in vitro </em>studies, CYP 3A4 is the major enzyme that is involved in the metabolism of itraconazole.</p><p><em>Excretion:</em></p><p>Itraconazole is excreted as inactive metabolites to about 35% in urine within one week and to about 54% with faeces. Renal excretion of the parent drug accounts for less than 0.03% of the dose, whereas faecal excretion of unchanged drug varies between 3-18% of the dose.</p><p>As re-distribution of itraconazole from keratinous tissues appears to be negligible, elimination of itraconazole from these tissues is related to epidermal regeneration. Contrary to plasma, the concentration in skin persists for 2 to 4 weeks after discontinuation of a 4-week treatment and in nail keratin &ndash; where itraconazole can be detected as early as 1 week after start of treatment &ndash; for at least six months after the end of a 3-month treatment period.</p><p>&nbsp;</p><p>Special Populations</p><p><em><u>Hepatic</u></em><em><u> </u></em><em><u>impairment</u></em></p><p>Itraconazole is predominantly metabolised in the liver. A single oral dose (100 mg capsule) was administered to 12 patients with cirrhosis and six healthy control subjects; Cmax, AUC and terminal half-life of itraconazole were measured and compared between groups. Mean itraconazole Cmax was reduced significantly (by 47%) in patients with cirrhosis. Mean elimination half-life was prolonged compared to that found in subjects without hepatic impairment (37 vs. 16 hours, respectively). Overall exposure to itraconazole, based on AUC was similar in cirrhotic patients and in healthy subjects. Data are not available in cirrhotic patients during long-term use of itraconazole. (See sections 4.2 Posology and method of administration, and 4.4 Special warnings and special precautions for use.)</p><p><em><u>Renal impairment</u></em></p><p>Limited data are available on the use of oral itraconazole in patients with renal impairment. Caution should be exercised when the drug is administered in this patient population.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Itraconazole:</em></p><p>Itraconazole has been tested in a standard battery of non-clinical safety studies. Acute toxicity studies with itraconazole in mice, rats, guinea pigs and dogs indicate a wide safety margin. Sub (chronic) oral toxicity studies in rats and dogs revealed several target organs or tissues: adrenal cortex, liver and mononuclear phagocyte system as well as disorders of the lipid metabolism presenting as xanthoma cells in various organs.</p><p>At high doses, histological investigations of adrenal cortex showed a reversible swelling with cellular hypertrophy of the zona reticularis and fasciculata, which was sometimes associated with a thinning of the zona glomerulosa. Reversible hepatic changes were found at high doses. Slight changes were observed in the sinusoidal cells and vacuolation of the hepatocytes, the latter indicating cellular dysfunction, but without visible hepatitis or hepatocellular necrosis. Histological changes of the mononuclear phagosystem were mainly characterised by macrophages with increased proteinaceous material in various parenchymal tissues.</p><p>There are no indications of a mutagenic potential of itraconazole.</p><p>Itraconazole is not a primary carcinogen in rats or mice. In male rats, however, there was a higher incidence of soft-tissue sarcoma, which is attributed to the increase in non-neoplastic, chronic inflammatory reactions of the connective tissue as a consequence of raised cholesterol levels and cholesterosis in connective tissue.</p><p>There is no evidence of a primary influence on fertility under treatment with itraconazole. Itraconazole was found to cause a dose-related increase in maternal toxicity, embryotoxicity, and teratogenicity in rats and mice at high doses. In rats, the teratogenicity consisted of major skeletal defects; in mice, it consisted of encephaloceles and macroglossia.</p><p>A global lower bone mineral density was observed in juvenile dogs after chronic itraconazole administration.</p><p>In three toxicology studies using rats, itraconazole induced bone defects. The induced defects included reduced bone plate activity, thinning of the zona compacta of the large bones, and increased bone fragility.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The inactive ingredients of the capsules are hypromellose, poloxamer, sucrose, and maize starch.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><!--[if gte vml 1]><v:shapetype id="_x0000_t202"
 coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
 <v:stroke joinstyle="miter"/>
 <v:path gradientshapeok="t" o:connecttype="rect"/>
</v:shapetype><v:shape id="_x0000_s1026" type="#_x0000_t202" style='position:absolute;
 left:0;text-align:left;margin-left:88.55pt;margin-top:14.1pt;width:418.35pt;
 height:14.65pt;z-index:15741440;mso-position-horizontal-relative:page'
 fillcolor="#d9d9d9" stroked="f">
 <v:textbox inset="0,0,0,0"/>
 <w:wrap anchorx="page"/>
</v:shape><![endif]--></p><p>Store below 25&deg;C.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Forming Ultraprotect PVC-PE-PVDC-PE-PVC / Aluminium blister pack.</p><p>Packs with either 4 or 15 capsules.</p><p><!--[if gte vml 1]><v:shapetype
 id="_x0000_t202" coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
 <v:stroke joinstyle="miter"/>
 <v:path gradientshapeok="t" o:connecttype="rect"/>
</v:shapetype><v:shape id="_x0000_s1026" type="#_x0000_t202" style='position:absolute;
 left:0;text-align:left;margin-left:88.55pt;margin-top:42.85pt;width:418.35pt;
 height:14.65pt;z-index:-17176064;mso-position-horizontal-relative:page'
 fillcolor="#d9d9d9" stroked="f">
 <v:textbox style='mso-next-textbox:#_x0000_s1026' inset="0,0,0,0"/>
 <w:wrap anchorx="page"/>
</v:shape><![endif]--></p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                SAJA Pharmaceuticals
Saudi Arabian Japanese pharmaceutical company limited Jeddah – Saudi Arabia

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                January 2024
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>